10-K 1 v305811_10k.htm FORM 10-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-K

 

xANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 25, 2011

or

 

¨TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission file number 000-51645

 

GLENROSE INSTRUMENTS INC.

(Exact name of Registrant as specified in its charter)

 

Delaware 20-3521719
(State or Other Jurisdiction of Incorporation or Organization) (IRS Employer Identification No.)
   
45 First Avenue  
Waltham, Massachusetts 02451
(Address of Principal Executive Offices) (Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (781) 622-1120

Securities registered pursuant to Section 12(b) of the Act: None

Securities registered pursuant to Section 12(g) of the Act:

 

Title of each class Name of each exchange on which registered
Common Stock, $0.01 par value N/A

 

 

  

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes ¨ No x

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Securities Act. Yes ¨ No x

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes x    No ¨

 

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of the registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. x

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer ¨ Accelerated filer ¨ Non-accelerated filer ¨ Smaller reporting company x

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ¨ No x

 

The aggregate market value of the voting shares of the registrant held by non-affiliates is not applicable because our common stock was not yet trading as of June 26, 2011.

 

As of March 22, 2012 the registrant’s shares of common stock outstanding were: 3,112,647.

 

WARNING CONCERNING FORWARD-LOOKING STATEMENTS

 

THIS ANNUAL REPORT ON FORM 10-K CONTAINS forward-looking statements within the meaning of the PRIVATE Securities Litigation Reform Act of 1995 and OTHER Federal Securities laws. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON OUR PRESENT INTENT, BELIEFS OR EXPECTATIONS, AND ARE NOT GUARANTEED TO OCCUR AND may not occur. ACTUAL RESULTS MAY DIFFER MATERIALLY FROM THOSE CONTAINED IN OR IMPLIED BY OUR FORWARD-LOOKING STATEMENTS AS A RESULT OF VARIOUS FACTORS.

 

WE GENERALLY IDENTIFY FORWARD-LOOKING STATEMENTS BY TERMINOLOGY SUCH AS “MAY,” “WILL,” “SHOULD,” “EXPECTS,” “PLANS,” “ANTICIPATES,” “COULD,” “INTENDS,” “TARGET,” “PROJECTS,” “CONTEMPLATES,” “BELIEVES,” “ESTIMATES,” “PREDICTS,” “POTENTIAL” OR “CONTINUE” OR THE NEGATIVE OF THESE TERMS OR OTHER SIMILAR WORDS. THESE STATEMENTS ARE ONLY PREDICTIONS. THE OUTCOME OF THE EVENTS DESCRIBED IN THESE FORWARD-LOOKING STATEMENTS IS SUBJECT TO KNOWN AND UNKNOWN RISKS, UNCERTAINTIES AND OTHER FACTORS THAT MAY CAUSE OUR, OUR CUSTOMERS’ OR OUR INDUSTRY’S ACTUAL RESULTS, LEVELS OF ACTIVITY, PERFORMANCE OR ACHIEVEMENTS EXPRESSED OR IMPLIED BY THESE FORWARD-LOOKING STATEMENTS, TO DIFFER.

 

THIS REPORT ALSO CONTAINS MARKET DATA RELATED TO OUR BUSINESS AND INDUSTRY. THESE MARKET DATA INCLUDE PROJECTIONS THAT ARE BASED ON A NUMBER OF ASSUMPTIONS. IF THESE ASSUMPTIONS TURN OUT TO BE INCORRECT, ACTUAL RESULTS MAY DIFFER FROM THE PROJECTIONS BASED ON THESE ASSUMPTIONS. AS A RESULT, OUR MARKETS MAY NOT GROW AT THE RATES PROJECTED BY THESE DATA, OR AT ALL. THE FAILURE OF THESE MARKETS TO GROW AT THESE PROJECTED RATES MAY HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS, RESULTS OF OPERATIONS, FINANCIAL CONDITION AND THE MARKET PRICE OF OUR COMMON STOCK.

 

SEE “ITEM 1A. RISK FACTORS,” “MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS” AND “BUSINESS,” AS WELL AS OTHER SECTIONS IN THIS REPORT, THAT DISCUSS SOME OF THE FACTORS THAT COULD CONTRIBUTE TO THESE DIFFERENCES. THE FORWARD-LOOKING STATEMENTS MADE IN THIS ANNUAL REPORT ON FORM 10-K RELATE ONLY TO EVENTS AS OF THE DATE ON WHICH THE STATEMENTS ARE MADE. EXCEPT AS REQUIRED BY LAW, WE UNDERTAKE NO OBLIGATION TO UPDATE OR RELEASE ANY FORWARD-LOOKING STATEMENTS AS A RESULT OF NEW INFORMATION, FUTURE EVENTS OR OTHERWISE. 

 

 

 

 
 

 

GLENROSE INSTRUMENTS INC.

 

ANNUAL REPORT ON FORM 10-K

FOR THE FISCAL YEAR ENDED DECEMBER 25, 2011

 

TABLE OF CONTENTS

 

PART I
     
Item 1. Business. 2
     
Item 1A. Risk Factors. 9
     
Item 1B. Unresolved Staff Comments. 12
     
Item 2. Properties. 12
     
Item 3. Legal Proceedings. 13
     
Item 4. Mine Safety Disclosures. 13
     
PART II
     
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. 14
     
Item 6. Selected Financial Data. 14
     
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations. 14
     
Item 7A. Quantitative and Qualitative Disclosures About Market Risk. 18
     
Item 8. Financial Statements and Supplementary Data. 18
     
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure. 19
     
Item 9A. Controls and Procedures. 19
     
Item 9B. Other Information. 19
     
PART III
     
Item 10. Directors, Executive Officers and Corporate Governance. 20
     
Item 11. Executive Compensation. 24
     
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. 26
     
Item 13. Certain Relationships and Related Transactions, and Director Independence. 28
     
Item 14. Principal Accountant Fees and Services. 29
     
PART IV
     
Item 15. Exhibits and Financial Statement Schedules. 30

 

1
 

 

GLENROSE INSTRUMENTS INC.

 

PART I

 

Item 1. Business.  

 

General

 

GlenRose Instruments Inc., or GlenRose Instruments, the Company, we, our, or us, and its subsidiaries, provides radiological services; operates a radiochemistry laboratory network; and provides radiological characterization and analysis; provides hazardous, radioactive and mixed waste management; and provides facility, environmental, safety, and industrial hygiene health management.

 

We primarily provide the services described above to the federal government and its prime contractors. We do not treat, store, transport or dispose of hazardous waste as part of our business. As part of our ongoing business, our laboratories generate small volumes of wastes, and we employ commercial firms to transport, treat, and dispose of the wastes. We currently operate a network of laboratories in four locations in the United States, or U.S.

 

GlenRose Instruments was incorporated in Delaware in September 2005. The Company operates through its wholly owned subsidiary, Eberline Services Inc., or Eberline Services, or ESI, and its subsidiaries. The subsidiaries of Eberline Services are Eberline Services Hanford, Inc., or ESHI, Eberline Analytical Corporation, or EAC, Benchmark Environmental Corp., and Lionville Laboratory Inc., or Lionville. At the beginning of 2007, all of our outstanding shares of common stock were held by an affiliated limited partnership, which distributed all of our shares to its partners on December 31, 2007. As of December 25, 2011, Eberline Services and its subsidiaries generated all of the revenues of the Company.

 

Our principal operational headquarters is located in Albuquerque, New Mexico, and our principal executive offices are located in Waltham, Massachusetts. We plan to maintain a website at the following address: www.glenroseinstruments.com. Our website address included in this Annual Report on Form 10-K is a textual reference only and the information in the website is not incorporated by reference into this Annual Report on Form 10-K. Through a link on our website to the Securities and Exchange Commission, or SEC, website, www.sec.gov, we intend to provide free access to our Annual Report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, or the Exchange Act, as soon as reasonably practicable after electronic filing with the SEC. The charters of our committees of the board of directors of the Company, and our Code of Business Conduct and Ethics for our directors, officers and employees, are also expected to be available on our website, and we intend to post on our website any waivers of, or amendments to, such code of ethics.

 

Segment Reporting

 

As of December 25, 2011, we have three segments – the Environmental Services segment, the Analytical Laboratories segment and the Instruments segment. The Environmental Services operating segment provides radiological and waste management services primarily to the federal government in connection with the cleanup of the former and present atomic weapons and energy sites operated by the federal government. The Analytical Laboratories operating segment provides analytical radiological services and involves the operation of a radiochemistry laboratory network and a radioactive check source manufacturing facility. The Instruments segment was formed in 2006 with the intent to acquire instrument companies, which have well-established and proven technology. This segment also includes the research and development of a new line of instruments that the Company expects to begin marketing efforts in 2012. As of the date of this report the Company has not made any commitments, nor has it acquired any instrument businesses. Acquisition of instrument businesses is no longer a focus in our strategy. See our consolidated financial statements included in ‘‘Item 15. Exhibits and Financial Statement Schedules’’ of this Annual Report on Form 10-K for further financial information on our operating segments.

 

Background and Market

 

Environmental and Analytical Laboratory Services

 

The principal regulatory drivers of the hazardous waste management industry are the Resource Conservation and Recovery Act, or RCRA, enacted in 1976, and the Comprehensive Environmental Response, Compensation and Liability Act of 1980, or CERCLA. RCRA requires waste generators to distinguish between “hazardous” and “non-hazardous” wastes, and to treat, store and dispose of hazardous waste in accordance with specific regulations. The collection and disposal of solid and hazardous wastes are subject to local, state and federal laws and regulations, which regulate health, safety, the environment, zoning and land use. CERCLA holds generators and transporters of hazardous substances, as well as past and present owners and operators of sites where there has been a hazardous release, strictly, jointly and severally liable for environmental cleanup costs resulting from the release or threatened release of a hazardous substance. An integral part of this regulatory and compliance scheme is the need to detect and measure contaminants in order to ensure compliance.

 

2
 

  

GLENROSE INSTRUMENTS INC.

 

Our present focus is on the detection and measurement of radioactive wastes and “mixed wastes” which consist of radioactive wastes and other hazardous materials. The federal government primarily generated these wastes during the development and production of nuclear weapons. The nuclear power industry is another source of radioactive wastes.

 

The Department of Defense, or DOD, and the Department of Energy, or DOE, have not had true annual fiscal-year budgets for the past three years and have been operating on continuing resolutions for environmental expenditures that include closure and remediation of military bases and cleanup of nuclear weapons facilities. The federal government maintained fiscal year 2011 funding for all programs through fiscal year 2012 via a continuing resolution process. These years also contained additional expenditures under the “stimulus” program. The 2013 fiscal year DOE budget is detailed in the annual Presidential budget requests from these departments to Congress. The DOE's fiscal year 2013 budget request is approximately $5.65 billion, a 5.8% decline from the base funding for environmental management, including $950 million for facility infrastructure deactivation and decontamination and $428 million for site services. The DOD budget request for 2013 is $613.9 billion, a 4.9 % decline from 2012. DOD has stated that there is a continuing need to ensure that the hazardous wastes present at these sites, sometimes located near population centers, do not pose a threat to the surrounding population, and, in connection with the closure of many military bases, there is an economic incentive to make sure that the environmental restoration enables these sites to be developed commercially by the private sector. The DOE has long recognized the need to stabilize and safely store nuclear weapons materials and to clean up areas contaminated with hazardous and radioactive waste.

 

Our radiological and waste management services are employed primarily by the federal government in connection with the cleanup of the former and present atomic weapons and energy sites operated by the federal government.

 

Analytical Instruments

 

In 2008, we began limited research and development in nuclear instrumentation with the intent to develop a new line of instruments. The development budget for the first instrument was estimated at approximately $250,000. As of December 25, 2011, the Company had spent approximately $140,000 towards the development of a prototype instrument. The research and development effort is substantially complete and the Company expects to begin marketing in 2012.

 

Analytical Laboratory Services

 

Services

 

We operate a network of four laboratories in the U.S. In addition to two radiochemistry laboratories, we also operate a stable chemistry laboratory, which provides analyses for traditional samples and for radioactive mixed waste samples. Radiochemistry is an analysis technique to determine the presence and extent of radioactive materials. The Company and its predecessors have served the nuclear industry since 1948 with the opening of a laboratory in Richmond, California. In addition to the Richmond laboratory, we have laboratories in Oak Ridge, Tennessee and Exton, Pennsylvania. We also operate a radioactive “check source” manufacturing facility in Albuquerque, New Mexico. Check sources are small, radioactive standards and are primarily used in the calibration of testing and analytical equipment.

 

We provide a wide variety of sample analyses for government agencies, industry and nuclear utilities. The radionuclides or radioactive substances analyzed are in many chemical and physical forms, often in low concentrations and in a variety of matrices. These matrices include:

 

  · Surface and potable water · Aquatic and land animals
  · Sea water · Particulate fallout
  · Rain water · Urine and feces bioassay
  · Air filters · Reactor coolants and effluents
  · Soils and sediments · Irradiated reactor fuel
  · Food stuffs · Fissionable material
  · Vegetation · Low-level radioactive waste

 

3
 

 

GLENROSE INSTRUMENTS INC. 

 

We have extensive experience in the transuranic characterization of samples generated by the nuclear utility industry, by nuclear fuel processors, and by DOE and DOD facilities. Transuranic isotopes are those radioactive substances found in the atomic weapons and nuclear industries that must be isolated and disposed of in order to produce clean sites that can be returned to industrial use. We have specifically designed procedures to dissolve any refractory transuranic substances that may be present in samples from the nuclear fuel cycle. We can also perform radio-bioassays to detect and quantify radioactive substances in body fluids and excretions. Our laboratories use a broad range of analytical techniques and instrumentation. However, we work in the environmental range of analyses and do not undertake to perform high-level (hot laboratory) analyses.

 

Our stable chemistry analysis laboratory in Exton, Pennsylvania offers a full range of capabilities and a large capacity to support environmental laboratory programs. Water, soil, solid waste and air samples are analyzed for a wide variety of organic, inorganic and physical parameters using a variety of Environmental Protection Agency protocols and American Society for Testing and Materials methods. Routine service capabilities include organic chemicals, metals, wet chemistry and physical properties. Ancillary services include field sampling, field screening, data interpretation, method development and validation, onsite laboratories, mobile laboratories, analytical specifications preparation (quality assurance project plans, sampling and analysis plans) and data storage.

 

Regulation

 

While our business has benefited substantially from increased governmental regulation of hazardous wastes, the environmental services industry itself has become the subject of extensive and evolving regulation by federal, state and local authorities. Environmental testing laboratories like those we operate are subject to a variety of certifications. We believe that we have acquired all operating permits and approvals required for the current operation of our business. We make a continuing effort to anticipate regulatory, political and legal developments that might affect operations, but are not always able to do so. Compliance with federal state and local environmental provision has only a nominal effect on current or anticipated capital expenditures and has had no material effect on earnings or our competitive position. We cannot predict the extent to which any environmental legislation or regulation that may be enacted or enforced in the future may affect our operations.

 

Our laboratories hold the appropriate permits and licenses from the DOE, DOD, United States Corps of Engineers, Navy, and Nuclear Regulatory Agency and from 26 states.

 

Clients and Contracts

 

The largest component of our laboratory business is with the federal government and its prime contractors. We service more than 100 clients overall. We generally have long-standing relationships with our clients, averaging more than ten years with our top ten clients. Our clients include federal agencies, prime contractors to the federal government, state regulatory agencies and leading companies in the environmental marketplace.

 

Our strategy is to develop and maintain ongoing relationships with a diversified group of customers who have recurring needs for environmental services. We strive to be recognized as a reliable and high quality supplier of laboratory testing services based upon quality, responsiveness, customer service, information technologies, breadth of analytical techniques and cost effectiveness.

 

Laboratory pricing is based upon fixed unit pricing. Clients are invoiced for each analysis based on a fixed price for each substance that is analyzed, the type of report and quality assurance desired, the turn-around time, and the total price is determined by the number of corresponding analyses. Discounts may be provided for large volumes. Premiums are added for faster turn-around times of analyses. The laboratories have no cost-plus-fixed-fee contracts.

 

We provide our services under contracts and purchase orders. We bill all of our laboratory clients as analyses are completed and data packages are submitted to the client. We do not progress bill or recognize revenue on either an hourly-fee basis or on a percentage of completion. Analyses are normally completed and invoiced within one month after sample receipt from the client.

 

Environmental Services

 

Services

 

Our environmental specialists provide a wide range of services for radiological characterization and analysis; hazardous, radioactive and mixed waste management; and environmental, safety and health management. These services include program development, implementation and assessment; regulatory analysis, strategy development, permitting and compliance; and environmental liabilities management through such techniques as pollution prevention and application of best management practices. Our field services personnel provide radiological and industrial hygiene control and monitoring.

 

4
 

 

GLENROSE INSTRUMENTS INC.

 

Our major environment services client is the federal government, either directly or through its prime contractors. Our experience dates back to 1989 when we had our first contracts at the DOE’s Los Alamos and Waste Isolation Pilot Plant, or WIPP.

 

Our core competencies in environmental services are hazardous and radioactive waste characterization, waste management, and multimedia environmental regulatory compliance. Environmental regulatory compliance capabilities include multimedia environmental program development, implementation and assessment, including in the following areas:

 

·Air quality;
·Water quality (drinking water, storm water, wastewater, surface water and groundwater);
·Waste management (sanitary, solid, hazardous, radioactive, mixed and toxic substances); and
·Soil and subsurface quality (bioremediation strategies for petroleum-contaminated soils and characterization and investigation of subsurface contamination).

 

As an outgrowth of its radiological characterization expertise, our staff developed, for its own use, a gamma spectral analysis software tool, or SNAP™, which we have used on projects at Los Alamos National Laboratory, or Los Alamos, Rocky Flats Environmental Technology Site, and Idaho National Engineering and Environmental Laboratory, or Idaho National Laboratory. This software tool allows an experienced gamma spectral analyst more flexibility in performing peak identification, source modeling, and assay calculations than other similar, commercially available software. SNAP is used by customers at Los Alamos, Sandia National Laboratories, and at the U.K. atomic agency in Aldermaston, England.

 

Clients and Contracts

 

We manage and perform certain services for a variety of clients at Los Alamos, Idaho National Laboratory, Oak Ridge National Laboratory, or Oak Ridge, Argonne National Laboratories, and commercial sites nation-wide. At Los Alamos we have supported waste management and environmental protection programs since 1989. Our work is generally performed under cost plus fixed fee or task order contracts. We have provided radiological characterization services in support of closure activities at various sites across the country, including Alameda Naval Air Station in California and Walter Reed Hospital in Maryland. We have provided radiological characterization in support of waste retrieval operations at Idaho National Laboratory since 2003. In New Mexico, we have provided on-call, statewide hazardous materials incident response services to the New Mexico Environment Department since 1997.

 

Our waste management expertise includes comprehensive waste certification and characterization support activities for transuranic wastes destined for the Waste Isolation Pilot Plant, or WIPP. We have provided WIPP certification support at numerous DOE sites including the Hanford Reservation Site, or Hanford, Los Alamos, Idaho National Laboratory, Oak Ridge, Argonne National Laboratory-East and Lawrence Berkeley National Laboratory, and we have operated mobile transuranic waste characterization systems at Nevada Test Site and Argonne National Laboratory-East.

 

Since 1994, ESHI has provided radiological and industrial hygiene support, quality assurance, and safety services as a pre-selected subcontractor to both, Bechtel Hanford, Inc., or Bechtel, and Washington Closure Hanford, LLC, or WCH, at the Hanford Reservation. The Hanford Reservation is the largest complex within the DOE complex and the cleanup program is anticipated to extend beyond 2035. From 1994-2011, ESHI generated over $212.0 million in revenue from subcontracting work between the two contractors.

 

Until September 2005, ESHI operated under a subcontract agreement with Bechtel. When Bechtel’s contract expired on August 30, 2005 the DOE awarded the successor contract, the River Corridor Contract, or RCC, to WCH. WCH pre-selected ESHI as a subcontractor, and we continue to provide services to the site-wide cleanup effort. The RCC contract has substantial fee incentives for the team to complete the project by the end of government fiscal year 2013. ESHI’s current contract relationship with WCH is on a year-to-year basis, with extensions to the base contract through 2015. As with all contracts of this nature, our contract can be canceled on relatively short notice at the convenience of the federal government. Based in Richland, Washington, ESHI has approximately 175 employees. ESHI holds a contract with the Hanford Atomic Metal Trades Council labor bargaining unit and employs radiological control and industrial hygiene technicians to support Hanford Reservation projects. The Hanford Reservation contract with WCH is the largest held by us and accounts for approximately 62% of our total revenues.

 

At the Hanford Reservation site, we provide radiation protection services for the excavation, decontamination, and decommissioning of reactors, area surveillance maintenance and transition facilities, area remedial action and waste disposal sites, the Environmental Restoration Disposal Facility for the underground disposal of low-level wastes, the ground water project and the complex decontamination and decommissioning of the plutonium processing facility. The services provided by our radiological personnel include:

 

5
 

  

GLENROSE INSTRUMENTS INC.

 

·Maintaining adequate staffing of radiological control technicians and radiological control supervisors for the projects to detect and prevent the exposure of personnel to radiation;  
·Performing and document radiation, contamination and airborne surveys; 
·Writing and approve radiological work permits; 
·Writing and implementing procedures and work instructions to ensure compliance with federal regulations for conducting work in areas that cause exposure to radioactivity; 
·Providing program and inventory support for the radiological instrumentation and source control programs; 
·Maintaining and providing input for radiological worker and workplace monitoring metrics; 
·Providing radiation surveys of large contaminated open areas on the Hanford Reservation site using proprietary global positioning system, or GPS, and laser-assisted radiological mapping systems; and 
·Maintaining a cadre of certified instructors that provide radiological training.

 

We have established an excellent record for working safely in an environment consisting of radioactively contaminated condemned buildings and nuclear reactors, contaminated excavation sites with steep slopes and trenches, and in the vicinity of heavy equipment. In spite of the fact that our technicians and supervisors are deployed daily to work in excavation sites, old buildings and facilities, we have had only one lost-time injury since 1995. We recently completed more than two million hours worked without lost-time injury on the RCC.

 

Government Contracts

 

We must comply with and are affected by laws and regulations relating to the formation, administration and performance of U.S. government contracts. These laws and regulations, among other things:

 

·Require certification and disclosure of all cost or pricing data in connection with certain contract negotiations; 
·Impose acquisition regulations that define allowable and unallowable costs and otherwise govern our right to reimbursement under certain cost-based U.S. government contracts; and 
·Restrict the use and dissemination of information classified for national security purposes and the exportation of certain products and technical data.

 

U.S. government contracts are conditioned upon the continuing availability of congressional appropriations. Long-term government contracts and related orders are subject to cancellation if appropriations for subsequent performance periods become unavailable. Congress usually appropriates funds on a fiscal-year basis even though contract performance may extend over many years. Consequently, at the outset of a program, the contract is usually partially funded, and Congress annually determines if additional funds are to be appropriated to the contract. The federal government has increasingly moved away from cost-reimbursable contracts in favor of fixed price, task-order contracts. Multiple companies are awarded indefinite delivery, indefinite quantity master ordering agreements and compete against each other for the task orders released on the master agreement.

 

The U.S. government, and other governments, may terminate any of our government contracts and, in general, subcontracts, at their convenience, as well as for default based on performance. Upon termination for convenience of a cost reimbursement contract, we normally are entitled to reimbursement of allowable costs plus a portion of the fee. The amount of the fee recovered, if any, is related to the portion of the work accomplished prior to termination and is determined by negotiation. A termination arising out of our default could expose us to liability and have a material adverse effect on our ability to compete for future contracts and orders.

 

In addition, our U.S. government contracts (or those of the prime contractors) typically span only the base year with provisions for multiple option years. The U.S. government generally has the right to not exercise option periods and may not exercise an option period if the agency is not satisfied with our performance of the contract. U.S. government contracts generally contain provisions that allow the U.S. government to unilaterally suspend us from receiving new contracts pending resolution of alleged violations of procurement laws or regulations, reduce the value of existing contracts, issue modifications to a contract and control and potentially prohibit the export of our services and associated materials.

 

For the fiscal years ended December 25, 2011 and December 26, 2010, the federal government and its prime contractors accounted for more than 90% of our consolidated revenues. Two contracts accounted for 69% of our consolidated revenues. Any disruption in government funding, our relationship with the government or our major clients could have a material adverse impact on our financial condition. In addition, the inability to win new government contracts would have a material adverse effect on our business and financial condition.

 

6
 

 

GLENROSE INSTRUMENTS INC.

 

Competition

 

We believe that the principal competitive factors in all areas of our business are:

 

·technical proficiency;
·operational experience; 
·price; 
·breadth of services offered; and 
·local presence.

 

We compete with a diverse array of small and large organizations including the following:

 

·national or regional environmental management firms; 
·national, regional and local architectural, engineering and construction firms; 
·environmental management divisions or subsidiaries of international firms; 
·engineering, construction and systems companies; and 
·hazardous waste generators that have developed in-house capabilities.

 

Proprietary Technology

 

We have developed substantial proprietary technology and have established and maintain an extensive knowledge of the leading commercially available technologies. We incorporate these technologies into the environmental services that we provide to our customers. We currently hold three patents and 15 trademarks in the U.S., and we license software and other intellectual property from various third parties. We enter into confidentiality agreements with certain of our employees, consultants and corporate partners, and control access to software documentation and other proprietary information. We believe that we hold adequate rights to all intellectual property used in our business and that we do not infringe upon any intellectual property rights held by other parties.

 

We have several proprietary technologies that we believe give us a competitive advantage by offering unique services that benefit our clients, including:

 

·SNAP TM (Spectral Nondestructive Assay Platform); 
·SGS TM (Segmented Gate System);
·GPERS TM (Global Positioning Environmental Radiological Surveyor); and  
·LARADS TM (Laser-Assisted Ranging and Data System). 

 

SNAP: Spectral Nondestructive Assay Platform

 

Each transuranic analysis is comparatively expensive due to the rigorous accuracy and quality assurance requirements dictated by federal and state law. Another cost consideration to DOE is that the disposal of transuranic waste at the WIPP is significantly more expensive than the disposal of routine low-level radioactive waste. Therefore, we have identified a secondary opportunity to provide a less expensive onsite analysis of uncharacterized waste to distinguish these wastes at the generator’s site. SNAP is the technology we developed in response to this need. SNAP is an onsite and non-intrusive method to radiologically characterize the contents of a wide array of wastes at lower costs than other methods. The use of mathematical models allows the Company to adequately characterize and quantify wastes in less than one-half the time typically required to achieve comparable results. SNAP makes it possible to accurately characterize wastes of unknown composition with minimal effort.

 

Defensible, cost-effective waste characterization capability is essential to the remediation of contaminated sites and waste management. SNAP yields the following benefits:

 

·Cost savings over standard characterization techniques; 
·Small, light-weight, portable and battery-powered instrumentation that lends its use to remote deployment; 
·Digital storage of data on the locations and concentrations of contaminants and display of the data in near real-time; 
·Ability to assay all sizes and shapes of waste packages; 
·Portable non-destructive assay technology yielding excellent detection limits in addition to accurate radionuclide quantification; and
7
 

 

GLENROSE INSTRUMENTS INC. 

 

·Data on isotopes, concentration levels and locations (rather than just activity levels).

 

Considering the high cost of transuranic waste management and disposal, reductions such as these have produced significant cost savings for our clients. We believe that the use of SNAP has reduced disposal costs at the WIPP site.

 

SGS: Segmented Gate System

 

The SGS is a technology that separates radioactively contaminated soil from clean soil. The SGS is a combination of sophisticated conveyor systems, radiation detectors and computer controls that remove contaminated soil from a moving feed supply on a conveyor belt. It significantly reduces the volume of contaminated soils requiring treatment and disposal, enabling large cost savings. The clean soil stream is diverted for return to the site or cheaper disposal options. The SGS has been successfully used to remediate over 200,000 cubic yards of plutonium-contaminated soil on Johnston Atoll, which is a large environmental restoration project, which involves a significant volume reduction of radioactively contaminated soil. The system has also processed over 15,000 cubic yards of soils contaminated with various radionuclides at many DOE and DOD sites across the U.S. The system was last employed at a commercial site in Louisiana to remediate soil contaminated with radionuclides from oil field operations.

 

Radiological Mapping Systems

 

We offer two types of radiological mapping technologies, GPERS and LARADS.

 

Common features of the two radiological mapping systems are as follows:

 

·Both systems collect and store in electronic files the positional coordinates and radiological readings on a point-per-second basis. These field files are then downloaded and processed with software to produce both a color-coded (based on radiological reading) map of the survey trace overlaid upon a computer-aided-design base map or digital photo of the site or area; and 
·Survey detectors can be hand-carried or mounted on a vehicle for large area surveys.

 

Use of the GPERS and LARADS systems offers several advantages over traditional radiological surveys, which involve manual collection and documentation of objective data and manual data archival, management, and assembly. These advantages include:

 

·The GPERS system constantly updates position data from global positioning satellites accurate to within less than 0.5 meters. The LARADS system utilizes an auto tracking laser range finding system to provide the same positioning data accurate to less than inch for those situations where satellite data are unavailable (i.e., indoors or under trees next to buildings); 
·GPERS and LARADS automatically acquire and store radiation and positioning data as the technician moves from location to location providing a continuous record in retrievable format; 
·The radiation data is acquired every second and can be merged, averaged and evaluated without subjective operator interpretation; 
·The need for manual data entry is eliminated because data is collected and stored in database format. This eliminates transcription errors and position errors, and also allows the position data to be reported in any commonly used coordinates system; 
·Ability to report on data collected within 24 hours; and 
·Savings in accelerated performance.

 

GPERS: Global Positioning Environmental Radiological Surveyor is a lightweight survey platform used for performing radiological surveys in open land areas. GPERS reduces labor requirements to characterize large outside land areas for radiological contaminants, thereby significantly reducing project costs. This technology merges standard radiation monitoring equipment with satellite global positioning to accurately locate and quantify areas of elevated radioactive contamination. The accuracy of the sophisticated equipment automatically produces repeatable and verifiable coordinates, thus reducing requirements for extensive grid establishment. The GPERS is coupled with conventional radiation detectors for outdoor radiological surveys where positional accuracies of less than one meter are sufficient.

 

LARADS: Laser-Assisted Ranging and Data System is a radiological surveying instrument that automates the collection of indoor radiation measurement data. LARADS reduces labor costs to characterize the interior surfaces of buildings where GPS tracking is unavailable. This system integrates standard radiation monitoring equipment with a laser positioning total system to locate elevated levels of radioactive contamination. Both GPERS and LARADS databases can be overlaid on digital photographs, computer aided design drawings, and drawings generated by the system to visually depict the characterization data.

 

8
 

 

GLENROSE INSTRUMENTS INC.

  

LARADS offers two advantages over the GPERS systems in that:

 

·It can be used inside a building or facility, while the GPERS requires a view of the sky; and 
·Its positional accuracy, and hence detector velocity, are much more precise. This allows greater control of survey scan rates, and post-processed minimum detection analyses are much more accurate. The LARADS includes an alarm to alert the surveyor if the velocity user-set point is exceeded.

 

The resulting color-coded data maps are helpful tools for evaluating site conditions and providing pre-job briefings. This system is coupled with conventional radiation detectors for indoor surveys or surveys where higher positional accuracy is desired (less than two centimeters). The LARADS system can be (and has been successfully) mounted on automated platforms to allow surveys of walls and ceilings without the use of ladders and scaffolds, minimizing the risks to personnel accessing these types of equipment. During 2010, the Company received national recognition for the development of a cart-based version of its system that was used to characterize legacy train tracks at the Hanford site.

  

Research and Development

 

In 2008, we began limited research and development in nuclear instrumentation with the intent to develop a new line of instruments. The development budget for the first instrument was estimated at approximately $250,000. As of December 25, 2011, the Company had spent approximately $140,000 towards the development of a prototype instrument. The research and development effort is substantially complete and the Company expects to begin marketing efforts in 2012.

 

Employees

 

As of December 25, 2011, the Company and its subsidiaries employed approximately 308 active full-time employees and 20 part-time employees. Included in this group are approximately 140 employees at the Hanford Reservation who are covered under a collective bargaining agreement. One of our subsidiaries has a contract with the Hanford Atomic Metal Trades Council. We have a good relationship with the union. In general, we believe that our relationship with our employees is satisfactory.

 

Item 1A. Risk Factors.

 

Our business faces many risks. The risks described below may not be the only risks we face. Additional risks that we do not yet know of, or that we currently think are immaterial, may also impair our business operations or financial results. If any of the events or circumstances described in the following risks occurs, our business, financial condition or results of operations could suffer and the value of our securities could decline. Investors and prospective investors should consider the following risks and the information contained under the heading ‘‘Warning Concerning Forward-Looking Statements’’ before deciding whether to invest in our securities.

 

We have a history of losses and may not remain profitable.

 

We reported a net income for the years ended December 25, 2011 and December 26, 2010 but we reported net losses for the years ended December 27, 2009 and December 28, 2008. As the DOE closes facilities, it may result in fewer projects and samples for analytical laboratory services and environmental services. Our ability to remain profitable is dependent on numerous factors, some of which the Company cannot control or influence. Political pressure to reduce government spending or to reduce the federal deficit could materially impact our business.

 

We are substantially dependent on contracts with the U.S. Government.

 

Over 90% of our revenue is derived, directly or indirectly, from contracts with the federal government, and our sales concentration is skewed towards two primary customers. Two contracts accounted for 69% of our consolidated revenues. Any disruption in government funding or in our relationship with the government could have a material adverse impact on our financial condition. In addition, many of our contracts with federal government agencies require annual funding approval and may be terminated at their discretion. A reduction in spending by the federal or state agencies could limit the continued funding of our existing contracts with them and could limit our ability to obtain additional contracts. The inability to win new government contracts would have a material adverse effect on our business and financial condition.

 

9
 

 

GLENROSE INSTRUMENTS INC. 

 

Fixed-price contracts expose us to losses in the event of unanticipated cost increases.

 

Our laboratories conduct a fixed-price sample business, which constitutes approximately 22.5% of our consolidated revenues. Fixed-price contracts may have unanticipated or unforeseeable cost increases that could have a material adverse impact on our financial condition if we underbid these contracts. Fixed-price contracts protect clients but expose us to a number of risks. These risks include:

 

·underestimation of costs;
·increased energy and chemical prices;
·problems with the appropriate choice of technologies;
·unforeseen costs or difficulties;
·delays beyond our control; and
·economic and other changes that may occur during the contract period.

 

Future federal audits could materially affect our results of operations and financial condition.

 

It is possible that future federal audits performed by the Defense Contract Audit Agency, or DCAA, on cost-plus-fixed-fee and related types of government contracts may determine that there have been overpayments to us by the government. Any related settlement of that sort may create a liability for the Company. In the past, settlements had the opposite effect with the Company recouping additional funds. The possibility, however, does exist for overbilling due to incorrect provisional overhead rates in a given year. As of December 25, 2011, the Company had approximately $135 million of unaudited costs associated with cost-type contracts dating back to fiscal year 2006.

 

We perform services under numerous subcontract agreements on cost-reimbursable contracts with the federal government. During the period from 1998 to 2003, the Company was party to a subcontract agreement with Johnson Control Northern New Mexico, or JCNNM, to provide services to Los Alamos on a cost-reimbursable basis. On May 14, 2007, the Company received notification from IAP-Northern New Mexico, or IAPNNM, the successor corporation to JCNNM, that the results of a Los Alamos audit for the period ending in 2003 determined that certain costs previously claimed and billed by the Company were subsequently deemed unallowable or otherwise not reimbursable. IAPNNM requested that we reimburse the amount of $321,836 that was paid to the Company during the subject time period. In January 2009, the Company protested the Los Alamos audit results claiming they were inaccurate and requested to resubmit a claim for the subject contract. The Los Alamos audit team agreed to review the audit results and adjust the claim as needed. As of December 25, 2011, Los Alamos had not reviewed our claim. In the event it is determined that we have to reimburse such amount in full, the resultant cost could materially affect our results of operations.

 

Our government contracts expose us to the possibility of substantial fines and penalties, governmental audits and investigations and suspension or debarment.

 

We face specific risks associated with government contracting, which include the risk of substantial civil and criminal fines and penalties for violations of applicable laws and regulations. Government contracting requirements are complex, highly technical and subject to varying interpretations. During the course of an audit, an agency may disallow costs if, for example, it determines that we improperly accounted for such costs in a manner inconsistent with government cost accounting standards. Under the typical “cost-reimbursable” government contracts that we perform, only those costs that are reasonable, allocable and allowable are recoverable in accordance with federal acquisition regulations and cost-accounting standards. In addition to damage to our business reputation, the failure to comply with the terms of one or more of our government contracts could also result in our suspension or debarment from government contract projects for a significant period of time. This would have a material adverse effect on our business.

 

Our nuclear waste management services subject us to potential environmental and other liabilities.

 

Our business of rendering services in connection with management of waste, including certain types of hazardous waste and low-level radioactive waste, subjects us to risks of liability for damages. Such liability could involve, without limitation:

 

·claims for  cleanup  costs,  personal  injury  or  damage  to  the environment  in  cases in  which  we are  held  responsible for the release of hazardous or radioactive materials;
·claims of employees, customers, or third parties for personal injury or property damage occurring in the course of our operations; and
·claims alleging negligence or professional errors or omissions in the planning or performance of our services.

 

In addition, we are subject to potentially large civil and criminal liabilities. The government could suspend or disbar us as a government contractor or hold us liable for any failure to abide by environmental laws and regulations.

 

10
 

 

GLENROSE INSTRUMENTS INC. 

 

We are substantially dependent on current management, and if we fail to attract and keep senior management and key scientific and operating personnel, we may be unable to successfully pursue our growth strategy.

 

Our success depends on the contributions of our key management, especially our Chief Executive Officer, Arvin Smith, and our Chairman, John Hatsopoulos. Their respective ages are 82 and 77. We expect that our future market capitalization will be in significant part dependent on the reputation of these individuals. We do not have employment contracts with either of these individuals, and we do not maintain key person insurance on any of our employees, officers, or directors. The loss of the services of either of these individuals would likely have a material adverse effect on our business and prospects.

 

Our success also depends on our ability to retain and expand our staff of qualified managerial and technical personnel. Qualified individuals are in high demand and are often subject to competing offers. We cannot be certain that we will be able to attract and retain the qualified personnel we need for our business. If we are unable to hire additional personnel as needed, it would likely have a material adverse effect on us.

 

Our operating results fluctuate across quarters due to the nature of our business.

 

Our quarterly revenues, expenses and operating results may fluctuate significantly due to a number of factors, including:

 

·the seasonality of the spending cycle of our public sector clients, notably the federal government;
·employee hiring and utilization rates;
·the number and significance of client projects commenced and completed during a quarter;
·delays incurred in connection with a project;
·the ability of our clients to terminate projects without penalties; and
·weather conditions.

 

Historically, we experience lower revenues in the first calendar quarter primarily due to weather conditions. Also, because we have a heavy concentration of federal government contracts, the federal appropriations process may significantly affect our operating results. However, variations in any of these factors could cause significant fluctuations in our operating results from quarter to quarter.

 

Our industry is subject to intense competition, and several of our competitors are larger than us.

 

In our radiological services business, we compete with many national environmental and consulting firms, and in our laboratory business we compete with many regional or niche firms. Some of our larger competitors benefit from economies of scale and have better access to bonding and insurance markets at a lower cost than we can achieve. The entry of large systems contractors and international engineering and construction firms into the environmental services industry has increased competition for major federal government contracts and programs.

 

The analytical instrument business is subject to intense competition. Competitors would include many other companies that offer products and services similar to ours. Many of our potential competitors have longer operating histories, large customer bases, greater brand recognition and significantly greater financial, marketing and other resources. Certain of our potential competitors may be able to devote greater resources to marketing, adopt more aggressive pricing policies and devote substantially more resources to developing their products. We may be unable to compete successfully against current and future competitors, and competitive pressures may have a material adverse effect on us.

 

Our business is affected by general economic conditions and related uncertainties affecting markets in which we operate. The current economic conditions could adversely impact our business in 2012 and beyond.

 

The current economic conditions could adversely impact our business in 2012 and beyond, resulting in reduced demand for our services, increased rate of order cancellations or delays, increased pressure on the prices for our samples; and greater difficulty in collecting accounts receivable.

 

11
 

 

GLENROSE INSTRUMENTS INC. 

 

There is no public market for our outstanding common stock, and there will be restrictions on transferability.

 

There is presently no public market for our outstanding common stock, and we cannot assure you that a public market will ever develop. Moreover, even if a public market develops, any sale of our outstanding common stock may be made only pursuant to an effective registration statement under federal and applicable state securities laws or exemptions therefrom. Realization of any gains on an investment in us will be principally dependent upon our ability to effectuate one or more liquidity-providing transactions.

 

We anticipate that if and when our common stock becomes publicly traded, such trading in the stocks of smaller companies like us is often thin, sporadic and characterized by wide fluctuations in trading prices, due to many factors that may have little to do with our operations or business prospects.

  

Trading of our common stock may be restricted by the SEC’s “penny stock” regulations which may limit a stockholder’s ability to buy and sell our stock.

 

The SEC has adopted regulations which generally define “penny stock” to be any equity security that has a market price less than $5.00 per share or an exercise price of less than $5.00 per share, subject to certain exceptions. If and when our common stock becomes publicly traded, it may be covered by the penny stock rules, which impose additional sales practice requirements on broker-dealers who sell to persons other than established customers and accredited investors. The penny stock rules require a broker-dealer, prior to a transaction in a penny stock not otherwise exempt from the rules, to deliver a standardized risk disclosure document in a form prepared by the SEC that provides information about penny stocks and the nature and level of risks in the penny stock market. The broker-dealer also must provide the customer with current bid and other quotations for the penny stock, the compensation of the broker-dealer and its salesperson in the transaction and monthly account statement showing the market value of each penny stock held in the customer’s account. The bid and offer quotations, and the broker-dealer and salesperson compensation information, must be given to the customer orally or in writing prior to effecting the transaction and must be given to the customer in writing before or with the customer’s confirmation. In addition, the penny stock rules require that prior to a transaction in a penny stock not otherwise exempt from these rules, the broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser’s written agreement to the transaction. These disclosure and suitability requirements may have the effect of reducing the level of trading activity in the secondary market for a stock that is subject to these penny stock rules. Consequently, these penny stock rules may affect the ability of broker-dealers to trade our securities. We believe that the penny stock rules discourage investor interest in and limit the marketability of our capital stock. Trading of our capital stock may be restricted by the SEC’s penny stock regulations, which may limit a stockholder’s ability to buy and sell our stock.

 

We have no intention to pay dividends.

 

We currently intend to retain earnings, if any, to fund the development and growth of our business and do not anticipate paying cash dividends in the foreseeable future. Our payment of any future dividends will be at the discretion of our board of directors after taking into account various factors, including our financial condition, operating results, cash needs and growth plans.

 

Item 1B. Unresolved Staff Comments.

 

None.

 

Item 2. Properties.

 

We own two properties and lease office space at several other locations. Our operational headquarters are located in Albuquerque, New Mexico and consist of office and storage space, and we lease our principal executive offices located in Waltham, Massachusetts. Our Analytical Laboratories segment includes a facility in Richmond, California consisting of approximately 20,000 square feet. The Company owns a facility in Albuquerque, New Mexico consisting of 14,449 square feet on four acres. The Company leases facilities in Exton, Pennsylvania consisting of 11,256 square feet and Oak Ridge, Tennessee consisting of approximately 10,000 square feet. Our Environmental Services segment leases office space in Richland, Washington and Los Alamos, New Mexico consisting of approximately 9,000 square feet. We believe that our facilities are appropriate and adequate for our current needs. As of December 25, 2011, we did not have any idle facilities as defined under the Federal Acquisition Regulations.

 

In 2009, the Company entered into an agreement, subject to closing conditions, with a buyer to sell the property in Albuquerque, New Mexico for approximately $1.9 million. The property is classified as “Assets held for sale” on the Company’s balance sheet as of December 25, 2011. The Company expects to complete the sale in 2012.

 

12
 

 

GLENROSE INSTRUMENTS INC.

 

Item 3. Legal Proceedings.

 

We are not currently a party to any material litigation, and we are not aware of any pending or threatened litigation against us that could have a material adverse effect on our business, operating results or financial condition.

 

Item 4. Mine Safety Disclosures.

 

Not applicable. 

 

13
 

 

GLENROSE INSTRUMENTS INC.

 

PART II

 

Item 5.Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

 

Market

 

Our common stock is not currently traded on any stock exchange or electronic quotation system.

 

Holders

 

As of March 22, 2012, the number of holders of record of our common stock was 27.

 

Dividends

 

We currently intend to retain earnings, if any, to fund the development and growth of our business and, do not anticipate paying cash dividends in the foreseeable future. Our payment of any future dividends will be at the discretion of our board of directors after taking into account various factors, including our financial condition, operating results, cash needs and growth plans.

 

Equity Compensation Plans

 

For disclosure of securities authorized for issuance under equity compensation plans please see “Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters”.

 

Recent Sales of Unregistered Securities

 

None.

 

Item 6. Selected Financial Data.

 

Not applicable.

 

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes appearing elsewhere in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. You should review “Item 1A. Risk Factors” beginning on page 9 of this Annual Report on Form 10-K for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

 

We are dependent on Federal spending, which may be affected by deficit reduction efforts in the current and succeeding fiscal years. Federal budgets are currently operating under “continuing resolution”. When a final federal budget is approved, our business may be impacted.

 

General Overview

 

For the year ended December 25, 2011, Eberline Services and its subsidiaries accounted for 100% of the Company’s sales. Eberline Services primarily provides services to the federal government contracting market for nuclear and environmental services. We believe the present level of government expenditures will continue in 2012, however, deficit reduction efforts may have an impact on our ability to secure new contracts in the future years.

 

14
 

 

GLENROSE INSTRUMENTS INC. 

 

Business Overview

 

We provide radiological characterization and analysis; hazardous, radiological, and mixed (radiological and hazardous) waste management; and environmental, safety and health services, primarily to the federal government. We provide labor-based consulting, engineering, and technical services, as well as measurement and detection services; we are not in the business of creating, treating, storing, transporting or disposing of hazardous waste. Our network of radiochemistry laboratories is an experienced provider of analytical radiological services. Radiochemistry is an analysis technique to determine the presence and extent of radioactive materials. We also operate a radioactive “check source” manufacturing facility in Albuquerque, New Mexico. Our laboratories are located in California, Pennsylvania and Tennessee. The laboratories generate a small amount of waste in the analytical processes. We dispose of all waste in accordance with specific guidelines. During 2010, the federal government increased spending dramatically on environmental programs within the DOE complex. The increased spending, which was largely associated with the government’s “stimulus” plan in conjunction with improved efficiencies at our Pennsylvania facility, resulted in profitable operating results in our laboratory segment.

 

We derive the majority of our revenues directly or indirectly from contracts with the federal and state governments. Two contracts account for approximately 69% of Eberline Services’ total sales: the RCC in Richland, Washington, and a contract with LANS at Los Alamos. At the Hanford Nuclear Reservation in Richland, Washington, we provide radiological support services to WCH, a prime contractor to the DOE. In Los Alamos, New Mexico, we provide technical services to LANS, a prime contractor to Los Alamos. Additionally, our laboratories derive the large majority of their revenues from the analysis of samples collected from government funded clean-up sites by the prime contractors or other subcontractors. Our check source manufacturing facility is also dependent on government contracts, as well as commercial entities like nuclear power plants. In total, only a minor portion of our laboratory revenues is derived from other government agencies and commercial customers.

 

Our Environmental Services business base is primarily comprised of cost-plus fee contracts. Under these contracts, we recover our allowable costs plus either a fixed fee or an incentive fee. For cost-plus contracts, we recognize revenue based on the actual costs we incur, plus earned fees. We bill cost-plus fixed fee contracts at approved, predetermined provisional billing rates. We adjust billing rates as needed to minimize over-billed or under-billed variances at contract closeout. Laboratory contracts are typically fixed-unit rate contracts, with a negotiated price for each sample analyzed.

 

Recent Accounting Pronouncements

 

For recent accounting pronouncements see “Note 1 - The organization and significant accounting policies” to our consolidated financial statements.

 

Critical Accounting Policies

 

For critical accounting policies see “Note 1 - The organization and significant accounting policies” to our consolidated financial statements.

 

Results of Operations

 

Fiscal Year Ended December 25, 2011 Compared with Fiscal Year Ended December 26, 2010

 

Revenues

 

Revenues in 2011 were $44,487,517 compared to $40,945,262 for the same period in 2010, an increase of $3,542,255 or 8.7%. The increase in revenues was due to an increase in our Environmental Services due to increased work at Hanford, Los Alamos and Argonne National Laboratory. The revenue in our Analytical Laboratory revenues decreased due to lower sample volume at our Richmond California laboratory.

 

Revenues from our Environmental Services in 2011 were $34,464,753 compared to $30,799,943 for the same period in 2010, an increase of $3,664,810 or 11.9%. Our Environmental Services contributed 77.5% to total revenues in 2011 compared to 75.2% for the same period in 2010. The increase in our Environmental Services revenue was due to increased work at Hanford and new work at Argonne National Laboratory and Los Alamos National Laboratory. At Hanford our efforts are centered on three contracts; the largest increase at Hanford was on the River Corridor contract, as that contract is at its peak this year. Work continued on our CH2M HILL Plateau Remediation Company, or CHPRC, contract at Hanford for radiological control technician support and we added additional contract work in radiological mapping for CHPRC. At Los Alamos our work changed from a long-term support contract to a contract which included an on-site screening facility and remediation support. We also began a multi-year contract for drilling of environmental monitoring wells. We also performed work on two contracts at the Argonne National Laboratory this period; the first was in support of a decontamination and demolition project and the second was in support of a characterization survey for both radiological and non-radiological contamination.

 

15
 

 

GLENROSE INSTRUMENTS INC.

 

Revenues from our Analytical Laboratories in 2011 were $10,022,764 compared to $10,145,319 for the same period in 2010, a decrease of $122,555 or 1.2%. Our Analytical Laboratories contributed 22.5% to total revenues in 2011 compared to 24.8% for the same period in 2010. The decrease in revenues was the result of decreased sample load primarily at our Richmond laboratory, offset with revenue increase at the Oak Ridge and Lionville laboratories.

 

Cost of Sales

 

The cost of sales in 2011 was $39,952,210 compared to $36,735,257 for the same period in 2010, an increase of $3,216,953 or 8.8%. The increase in cost of sales was primarily due to increased variable costs in both the Analytical Services and Laboratory segments. We increased the number of employees, subcontracts and direct materials. The cost of sales from our Environmental Services in 2011 was $31,213,256 compared to $28,255,733 for the same period in 2010, an increase of $2,957,523 or 10.5% primarily due to salaries of new employees and an increase in subcontracts. The cost of sales from our Analytical Laboratories in 2011 was $8,738,954 compared to $8,479,524 for the same period in 2010, an increase of $259,430 or 3.1%, primarily due to increased direct labor and direct materials. Our direct labor was affected by increased overtime required to meet response times despite our efforts to utilize our capacity more efficiently and establish better cost controls.

 

Gross Profit

 

Gross profit in 2011 was $4,535,307 compared to $4,210,005 for the same period in 2010, an increase of $325,302 or 7.7%. The gross profit margin decreased to 10.2% in 2011 from 10.3% for the same period in 2010. The increase in the gross profit was primarily due to the increase in revenue at Environmental Services. The gross profit from our Environmental Services in 2011 was $3,251,497 compared to $2,544,210 for the same period in 2010, an increase of $707,287 or 27.8%. The gross profit from our Analytical Laboratories in 2011 was $1,283,810 compared to $1,665,795 for the same period in 2010, a decrease of $381,985 or 22.9%.

 

Operating Expenses

 

General and administrative expenses in 2011 were $2,242,090 compared to $2,316,393 for the same period in 2010, a decrease of $74,305, or 3.2%. The change was due to salaries and fringe benefits that decreased by $147,663, offset by non-labor expenses, such as outside services and consultants, software and computer hardware upgrades and corporate travel that increased by $73,358.

 

Operating Income

 

The operating income in 2011 was $2,293,217 compared to $1,893,612 for the same period in 2010. The operating income consisted of $1,750,659 at the Environmental Services and $881,987 at the Analytical Laboratories, offset by corporate general and administrative expenses of $339,429 at the Instruments segment. The increase in operating income was due to the increased revenue in our Environmental Services segment. During the period we added direct personnel and were able to better utilize existing personnel in more direct roles on large contracts. The small decrease in our Analytical Laboratory revenues coupled with higher cost of sales resulted in lower margins and subsequently a lower operating income.

 

Other Income (Expense)

 

Other expenses in 2011 were $271,242 compared to $773,120 for the same period in 2010, a decrease of $501,879. Interest and other miscellaneous income in 2011 was $4,926 compared to $11,420 for the same period in 2010. The decrease was primarily due to a lower return on our overall invested cash balances. Interest expense in 2011 was $276,167 compared to $784,540 for the same period in 2010 due the repayment of principal amount of our related party convertible debentures outstanding, offset by amortization of the associated financing expenses associated with those convertible debentures.

 

Provision for Income Taxes

 

The Company recorded a tax provision of $736,054 in 2011 as the Company had fully utilized the majority of its available non separate return limitation year (SRLY) net loss carryforwards in prior periods, compared to a benefit of $28,907 in 2010.

 

Net Income/Loss

 

Net income in 2011 was $1,285,922 compared to $1,149,399 for the same period in 2010.

 

16
 

 

GLENROSE INSTRUMENTS INC.

 

Liquidity and Capital Resources

 

Consolidated working capital at December 25, 2011 was $2,372,997 compared to $5,281,340 at December 26, 2010. Included in working capital were cash, cash equivalents and short-term investments of $843,821 as of December 25, 2011, compared to $1,682,173 at December 26, 2010. The decrease in working capital was primarily due to the redemption of $4,875,000 of our 4% Convertible Debentures due 2013, including accrued interest, offset by cash generated from operations.

 

Cash provided by operating activities was $3,522,865 in 2011, compared to $943,008 for the same period in 2010. Our net receivables balance decreased to $3,932,918 in 2011 compared to $4,376,929 at December 26, 2010, resulting in an increase in cash of $444,011 primarily due to timing of invoicing related to a new contract at Los Alamos. Our unbilled contract receivables increased to $1,110,193 in 2011 compared to $370,887 at December 26, 2010, resulting in a decrease in cash of $739,306 due to timing of billings on our major cost-type contracts. Our prepaid expenses increased to $163,559 in 2011, compared to $97,450 at December 26, 2010, resulting in a decrease in cash of $66,109 primarily due to the payment and timing of normal operating expenses. Our other receivables decreased to $6,561 in 2011, compared to $58,464 at December 26, 2010, resulting in an increase in cash of $51,903. Our income tax receivable decreased to $0 in 2011, compared to $161,356 at December 26, 2010, resulting in an increase in cash of $161,356.

 

Accounts payable increased to $2,228,321 in 2011, compared to $653,130 at December 26, 2010 resulting in an increase in cash of $1,575,191 due to increased subcontract invoices on a new contract. Other accrued liabilities, including accrued expenses, accrued employee-related costs and income taxes payable, increased to $2,627,274 in 2011, compared to $2,354,038 at December 26, 2010, resulting in an increase in cash of $273,236. Our accrued interest, related party, balance decreased to $0 in 2011, compared to $48,750 at December 26, 2010, resulting in a decrease in cash of $48,750 due to interest payments.

 

The primary investing activities of the Company’s operations included the purchase of equipment. The Company continues to manage its capital expenditures very selectively and in 2011 used $488,875 for purchases of equipment. The Company’s financing activities used $3,872,342 of cash in 2011, primarily due to redemption of convertible debentures and payments on capital lease obligations offset by proceeds from a Term Note payable and an advance on a Line of Credit.

 

The Company owns property in Albuquerque, New Mexico. In 2009, the Company entered into an agreement, subject to closing conditions, with a buyer to sell the property for approximately $1.9 million. At December 25, 2011, $507,700 in land, $2,265,764 in buildings and improvements less $1,916,926 in accumulated depreciation is classified as “Assets held for sale” on the Company’s balance sheet. The assets held for sale balance of $1,178,306 also includes selling costs incurred to date of $37,477 and an accrual of $284,291 towards decommissioning of the site. In 2010, the Company submitted a detailed site assessment of the facility to the New Mexico Environmental Department, or NMED, as part of the closure process which was approved in June 2011. The Company characterized and classified all radiological waste associated with the facility and all waste was crated and packaged for disposal in 2010. In January 2011, the Company applied for a shipment permit to transfer the remaining waste to an appropriate facility, which was shipped during the fourth quarter. The Company is currently communicating with NMED on the report in preparation for the demolition of the building. The Company believes that it has adequately accrued for decommissioning of the site however it is possible that additional funds may be required as the Company commences the actual demolition process. The Company expects to complete the sale in 2012.

 

The Company believes that its existing resources, including cash and cash equivalents and future cash flow from operations, are sufficient to meet the working capital requirements of its existing business for the foreseeable future, including the next 12 months. We believe that our cash and cash equivalents, available borrowings under the Line of Credit, potential future property sales in Albuquerque, New Mexico and Richmond California and our ability to control certain costs, including those related to general and administrative expenses will enable us to meet our anticipated cash expenditures for the next 12 months. The Company’s long-term liabilities primarily include a Term Note secured by the Company’s real estate assets with a 7 year straight line amortization at Libor plus 3.50%.

 

On July 1, 2011, the Company redeemed the outstanding amount of the convertible debentures with Blum Strategic Partners IV, L.P., in the principal amount of $3,065,546, plus accrued interest. In connection with that transaction, the Company entered into a $500,000 Demand Note Agreement with John N. Hatsopoulos, the Company’s Chairman of the Board, and into a short-term $1,500,000 Demand Note Agreement with Arvin H. Smith, the Company’s Chief Executive Officer. Both demand note agreements accrued interest at the rate of 4.50% per year.

 

17
 

 

GLENROSE INSTRUMENTS INC.

 

On August 31, 2011, the Company entered into a credit agreement with Wells Fargo Bank for a $5,000,000 credit facility. The facility included a $1,000,000 term real-estate note with a 7 year straight line amortization, at Libor plus 3.5%, and up to $4,000,000 in a revolving line of credit for 5 years, at Libor plus 3.5%. On August 31, 2011, the Company borrowed $1,000,000 against the Term Note and $1,000,000 against the line of credit and used the proceeds to redeem the remaining balance of the convertible debentures and pay off the Demand Note Agreements with John N. Hatsopoulos and Arvin H. Smith.

 

As of December 25, 2011, there were no convertible debentures outstanding and the Demand Note Agreements were paid in full. The balance outstanding on the Term Note was $964,286 and the balance outstanding on the revolving line of credit was $0.

 

In March 2011 the Company retained the services of Raymond James & Associates, Inc. to act as its sole, external investment banking advisor in helping the Company evaluate strategic alternatives, including the possible sale of all or a material portion of the assets or securities of the Company to, or merger of the Company with, various third parties. On October 14, 2011, the Company terminated the engagement of Raymond James & Associates. Starting in the fourth quarter the Company increased its efforts in the development and manufacturing of a line of radiation monitoring instruments.

 

Seasonality

 

Our revenues may fluctuate significantly due to a number of factors, including:

 

·the seasonality of the spending cycle of our public sector clients, notably the federal government;
·employee hiring and utilization rates;
·the number of client projects commenced and completed during a quarter;
·delays incurred in connection with a project;
·the ability of our clients to terminate projects without penalties; and
·weather conditions at specific work sites.

 

Historically, we experience lower revenues in the first calendar quarter primarily due to weather conditions. Also, because we have a heavy concentration of federal government contracts the federal appropriations process may significantly affect our operating results. In the absence of appropriated budgets, the continuing resolution method of funding for departments such as DOE can result in restrictions on certain projects. Recent history indicates that government spending within DOE for our types of services is greater in our second and third fiscal quarters. Also, much of our effort in both Environmental Services and Analytical Laboratories are in support of decommissioning and remediation projects, which are easier to conduct in the warmer months. Since our services work is project based rather than production based, the award of a large contract for a limited time can cause fluctuations in the quarterly revenues. However, variations in any of the above factors could cause significant fluctuations in our operating results from quarter to quarter.

Inflation

 

We provide radiological services and operate a radiochemistry laboratory network. The major component of our costs is our personnel and associated fringes. Since the majority of our contracts are cost-plus based contracts, we are able to pass along the effects of inflation. In our laboratories, however, since our services are primarily priced on a fixed unit price basis we are less flexible to deal with the effects of inflation. Inflation may cause our cost of goods sold to increase, and therefore lower our return on investment and depress our gross margins. The Analytical Laboratory revenue in 2011 was approximately 22.5% of total revenue as compared to 24.8% in 2010.

 

Off Balance Sheet Arrangements

 

The Company has no off balance sheet arrangements.

 

Item 7A. Quantitative and Qualitative Disclosures About Market Risk.

 

Not applicable.

 

Item 8. Financial Statements and Supplementary Data.

 

The information required by this item is included in “Item 15. Exhibits and Financial Statement Schedules” of this Annual Report on Form 10 K. 

 

18
 

 

 

 

GLENROSE INSTRUMENTS INC.

 

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

 

None.

 

Item 9A. Controls and Procedures.

 

Management’s Evaluation of Disclosure Controls and Procedures:

 

Our management including our Chief Executive Officer and Chief Financial Officer, after evaluating the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Annual Report on Form 10-K, or the Evaluation Date, have concluded that as of the Evaluation Date, our disclosure controls and procedures were effective to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified by the SEC, and that material information relating to our Company and any consolidated subsidiaries is made known to management, including our Chief Executive Officer and Chief Financial Officer, particularly during the period when our periodic reports are being prepared to allow timely decisions regarding required disclosure.

 

Management’s Annual Report on Internal Control over Financial Reporting:

 

The management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting in accordance with the Exchange Act. Management, including our Chief Executive Officer and Chief Financial Officer, conducted an evaluation of our internal control over financial reporting based on the framework and criteria established in Internal Control—Integrated Framework, issued by the Committee of Sponsoring Organizations of the Treadway Commission. This evaluation included review of the documentation of controls, evaluation of the design effectiveness of controls, testing of the operating effectiveness of controls and a conclusion of this evaluation. Based on this evaluation, management concluded that the Company’s internal control over financial reporting was effective as of December 25, 2011.

 

Our management, including our Chief Executive Officer and Chief Financial Officer, do not expect that our disclosure controls or our internal control over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls’ effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.

 

This Annual Report on Form 10-K does not include an attestation report of the Company’s registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by the Company’s registered public accounting firm pursuant to rules of the SEC that permit the Company to provide only management’s report in this Annual Report on Form 10-K.

 

Changes in Internal Control over Financial Reporting:

 

In connection with the evaluation referred to in the foregoing paragraph, we have identified no change in our internal control over financial reporting that occurred during the year ended December 25, 2011 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

Item 9B. Other Information.

 

None.

19
 

 

GLENROSE INSTRUMENTS INC.

 

PART III

 

Item 10. Directors, Executive Officers and Corporate Governance.

 

Executive Officers and Directors

 

The following table lists the current members of our board of directors and our executive officers. The address for our directors and officers is c/o GlenRose Instruments Inc., 45 First Avenue, Waltham, Massachusetts 02451.

 

Name   Age   Position
         
John N. Hatsopoulos   77   Chairman of the Board and Director
Arvin H. Smith       82 President, Chief Executive Officer and Director
Dr. Richard Chapman   66   Executive Vice President and Chief Operating Officer
Dr. Shelton Clark       64 Vice President, Services
Anthony S. Loumidis   47   Treasurer and Chief Financial Officer
Robert Aghababian (1)(2)   70   Director
Barry S. Howe (1)   56   Director
William J. Zolner (2)   68   Director

 

 

 

(1)Member of Audit Committee
(2)Member of Compensation Committee

 

John N. Hatsopoulos has been our Chairman of the Board since 2005. Mr. Hatsopoulos is one of the four founding members of GlenRose Partnership L.P., and was a General Partner of GlenRose Capital LLC, formed in 2000 as a leverage buyout firm focused on making acquisitions in the environmental services and instrumentation business areas. Since 2001, he has been the Chief Executive Officer of American DG Energy Inc. (NYSE Amex: ADGE), a company that offers clean onsite electricity, heat, hot water and cooling to businesses in the Northeast United States and he is the Chief Executive Officer of Tecogen Inc., a manufacturer of natural gas, engine-driven commercial and industrial cooling and cogeneration systems. Since 2000, he has also been a Partner and Managing Director of Alexandros Partners LLC, a financial advisory firm providing consulting services to early stage entrepreneurial ventures. Mr. Hatsopoulos is a co-founder of Thermo Electron Corporation, which is now Thermo Fisher Scientific (NYSE: TMO), and the retired President and Vice Chairman of the Board of Directors of that company. He is a member of the Board of Directors of EuroSite Power Inc., Ilios Inc., American CareSource Holdings, Inc. (NASDAQ: ANCI) and TEI Biosciences Inc., and is a former Member of the Corporation of Northeastern University and former member of the Board of Agenus Inc. (NASDAQ: AGEN). Mr. Hatsopoulos graduated from Athens College in Greece, and holds a bachelor’s degree in history and mathematics from Northeastern University, as well as honorary doctorates in business administration from Boston College and Northeastern University.

 

Our board of directors has determined that Mr. Hatsopoulos’ prior experience in senior finance positions at Thermo Electron Corporation where he demonstrated leadership capability and garnered extensive expertise involving complex financial matters, and his extensive knowledge of complex financial and operational issues qualify him to be a member of the board of directors.

 

Arvin H. Smith has been our President and Chief Executive Officer since 2005. Mr. Smith is one of the four founding members of GlenRose Partnership L.P., and was a General Partner of GlenRose Capital LLC, formed in 2000 as a leverage buyout firm focused on making acquisitions in the environmental services and instrumentation business areas. Mr. Smith was the Chairman of Thermo Instrument Systems Inc., a public subsidiary of Thermo Electron Corporation, which is now Thermo Fisher Scientific (NYSE: TMO), from 1997 until 2000, and was President and Chief Executive Officer of that company from 1986 until 1996. He was also an Executive Vice President and member of the operating committee of Thermo Electron. Mr. Smith joined Thermo Electron in 1970, where he held various senior management positions. Prior to joining Thermo Electron and during the early years of the space program from 1959 until 1970, he held positions at NASA headquarters in Washington, D.C, as chief of Solar and Chemical Power Systems in the office of Advanced Research & Technology and at the Jet Propulsion Laboratory. He was also employed by General Dynamics from early 1954 until 1959 as an electronic technician and test engineer in the Aircraft Nuclear Propulsion Programs and also served in the U.S. Navy from 1950 until 1954. Mr. Smith graduated with honors from Texas Christian University and holds bachelor’s degrees in physics and mathematics.

 

20
 

 

GLENROSE INSTRUMENTS INC.

 

Our board of directors has determined that Mr. Smith’s prior experience in senior finance positions at Thermo Electron Corporation, which is now Thermo Fisher Scientific (NYSE: TMO), where he demonstrated leadership capability and garnered extensive expertise involving complex financial matters, and his extensive knowledge of complex financial and operational issues qualify him to be a member of the board of directors.

 

Dr. Richard Chapman has been our Executive Vice President and Chief Operating Officer since 2005. Dr. Chapman is one of the four founding members of GlenRose Partnership L.P., and was a General Partner of GlenRose Capital LLC, formed in 2000 as a leverage buyout firm focused on making acquisitions in the environmental services and instrumentation business areas. Dr. Chapman was President, Chief Executive Officer and a Director of ThermoQuest Corporation, a subsidiary of Thermo Electron Corporation, which is now Thermo Fisher Scientific (NYSE: TMO), from 1995 until 2000. He was also Senior Vice President of Thermo Instrument Systems, Inc. from 1995 to 2000, and served as Chairman of the Board of Thermo BioAnalysis Corporation from 1995 to 1997, and a Director of Thermo Cardio Systems, Inc., both publicly held subsidiaries of Thermo Electron. He is also a founder and chairman of Axxiom Inc., and Harbinger Instrument Systems, Inc., and holds bachelor’s and master’s of science degrees from the University of North Texas, and a doctorate from Oregon State University.

 

Dr. Shelton Clark has been our Vice President, as well as the President of the Services Group since 2005. From 1990 to 2001, he served in a number of U.S. and international management positions with Thermo Instrument Systems Inc., a public subsidiary of Thermo Electron Corporation, which is now Thermo Fisher Scientific (NYSE: TMO). Dr. Clark received a bachelor’s of science degree from the University of North Texas and holds a doctorate degree from the University of Texas.

 

Anthony S. Loumidis has been our Chief Financial Officer and Treasurer since 2005. Mr. Loumidis devotes a portion of his business time to several other organizations; namely as a Chief Financial Officer of American DG Energy Inc. (NYSE Amex: ADGE), a company that offers clean onsite electricity, heat, hot water and cooling to businesses in the Northeast United States; as the Vice President and Treasurer of Tecogen Inc., a manufacturer of natural gas, engine-driven commercial and industrial cooling and cogeneration systems; as the Partner and President of Alexandros Partners LLC, a financial advisory firm; and as the Treasurer of Ilios Inc., is a high-efficiency heating products company. Mr. Loumidis was previously with Thermo Electron Corporation, which is now Thermo Fisher Scientific (NYSE: TMO), where he held various positions including National Sales Manager for Thermo Capital Financial Services, Manager of Investor Relations and Manager of Business Development of Tecomet, a subsidiary of Thermo Electron. Mr. Loumidis is a FINRA registered representative, holds a bachelor’s degree in business administration from the American College of Greece in Athens and a master’s degree in business administration from Northeastern University.

 

Robert Aghababian has been a member of our board of directors since 2005. Mr. Aghababian is a tax attorney and former employee of Thermo Electron Corporation, which is now Thermo Fisher Scientific (NYSE: TMO), where he served as the Director of Tax for seventeen years. Prior to Thermo Electron he served in a similar position for Pneumo-Abex Corporation. Mr. Aghababian received a bachelor’s degree in business administration from Northeastern University and is a graduate of Boston College Law School.

 

Our board of directors has determined that Mr. Aghababian’s prior experience in senior finance positions as the chief tax officer of Thermo Electron Corporation, which is now Thermo Fisher Scientific (NYSE: TMO), where he garnered extensive expertise involving complex financial matters including the understanding of complex corporate tax organizations and reporting, qualify him to be a member of the board of directors.

 

Barry S. Howe has been a member of our board of directors since 2006. Mr. Howe was the President, CEO and a director of Electronic Sensor Technology (OTC BB: ESNR) from 2007 to 2008. He was a Corporate Vice President of Thermo Electron Corporation, which is now Thermo Fisher Scientific (NYSE: TMO), from 2002 to 2004, in charge of the Measurement & Control Sector. Mr. Howe joined Thermo Electron Corporation in 1986 as an Assistant Corporate Controller and was named President of the Thermo Separation Products subsidiary of Thermo Instrument Systems Inc. in 1989. He served as President and Chief Executive Officer of Thermo BioAnalysis from 1995 to 1998 and President and Chief Executive Officer of Thermo Spectra from 1998 to 2000, and Thermo Optek from 1999 to 2000. In 2000, he became President of the Optical Technologies Sector of Thermo Electron, a sector with 20 business units and over $600.0 million in revenues. Prior to joining Thermo Electron, Mr. Howe was an audit manager with Arthur Andersen & Co. from 1977 to 1985. Mr. Howe received a bachelor’s degree in business administration from Boston University.

Our board of directors has determined that Mr. Howe’s prior experience in senior finance positions at various companies, where he demonstrated leadership capability and garnered extensive expertise involving complex financial matters, and his extensive knowledge of complex financial and operational issues qualify him to be a member of the board of directors.

 

21
 

 

GLENROSE INSTRUMENTS INC.

 

Dr. William J. Zolner has been a member of our board of directors since 2007. He is President of Eagle Analytical Services, Inc., a subsidiary of Professional Compounding Centers of America. From 1993 to 2003, Dr. Zolner worked in various leadership capacities for Thermo Electron Corporation, which is now Thermo Fisher Scientific (NYSE: TMO). From 1997 to 2001 he was President, CEO and Director of Onix Systems Inc., a Thermo Instruments public subsidiary. Prior to 1997, he was President of Thermo Instruments Controls, a wholly owned subsidiary of Thermo Instruments and predecessor of Onix Systems Inc. Dr. Zolner worked for Thermo Electron Corporation from 1971 to 1977 in the environmental instruments division. From 1978 to 1993, he held key management positions with divisions of The Bendix Corporation, Combustion Engineering, JWP Inc., and Lear Siegler Measurement Controls. Dr. Zolner received a bachelor’s degree and doctorate in chemical engineering from Northeastern University.

 

Our board of directors has determined that Dr. Zolner’s prior experience in senior finance positions at various companies, where he demonstrated leadership capability and garnered extensive expertise involving complex financial matters, and his extensive knowledge of complex financial and operational issues qualify him to be a member of the board of directors.

 

Each executive officer is elected or appointed by, and serves at the discretion of, our Board of Directors. Our officers will hold office until their successors are duly elected and qualified, or until their earlier resignation or removal. 

 

Family Relationships

 

There are no family relationships among members of our Board of Directors or executive officers.

 

Board of Directors

 

Our board of directors currently consists of five directors. In addition, our amended and restated by-laws provide that the authorized number of directors may be changed only by resolution of our board of directors. Each director shall serve for a term ending on the date of the first annual meeting following the annual meeting at which such director was elected; provided further, that the term of each director shall continue until the election and qualification of a successor and be subject to such director’s earlier death, resignation or removal.

 

Board Committees

 

Our board of directors has established an audit committee, established in accordance with Section 3(a)(58)(A) of the Exchange Act, and a compensation committee. All of the members of each of these standing committees are independent as defined under NASDAQ rules and, in the case of the audit committee, the independence requirements contemplated by Rule 10A-3 under the Exchange Act. The members of our audit committee are Messrs. Howe and Aghababian. The members of our compensation committee are Messrs. Zolner and Aghababian.

 

Audit Committee

 

The audit committee’s responsibilities include: 

 

·appointing, approving the compensation of, and assessing the independence of our independent auditor;
·overseeing the work of our independent auditor, including through the receipt and consideration of reports from the independent auditor;
·reviewing and discussing with management and our independent auditor our annual and quarterly financial statements and related disclosures;

 

·monitoring our internal control over financial reporting, disclosure controls and procedures, and code of business conduct and ethics;
·discussing our risk management policies;
·establishing policies regarding hiring employees from our independent auditor and procedures for the receipt and retention of accounting related complaints and concerns;
·meeting independently with our independent auditor and management; and
·preparing the audit committee report required by SEC rules to be included in our proxy statements.

 

All audit services and all non-audit services, except de minimis non-audit services, must be approved in advance by the audit committee. Our board of directors has determined that at least one of our audit committee members is an audit committee financial expert. That person is Barry S. Howe, who is also independent under NASDAQ rules.

 

22
 

 

GLENROSE INSTRUMENTS INC.

 

Compensation Committee

 

The compensation committee’s responsibilities include:

 

·annually reviewing and approving corporate goals and objectives relevant to compensation of our Chief Executive Officer;
·determining the compensation of our Chief Executive Officer;
·reviewing and approving, or making recommendations to our board of directors with respect to, the compensation of our other executive officers;
·overseeing an evaluation of our senior executives;
·overseeing and administering our cash and equity incentive plans; and
·reviewing and making recommendations to our board of directors with respect to director compensation.

 

Corporate Governance

 

We believe that good corporate governance is important to ensure that, as a public Company, we will manage for the long-term benefit of our stockholders. In that regard, we have established and adopted charters for the audit committee and compensation committee, as well as a Code of Business Conduct and Ethics applicable to all of our directors, officers and employees.

 

Section 16(a) Beneficial Ownership Reporting Compliance

 

Section 16(a) of the Exchange Act requires the officers and directors of the Company, and persons who own 10% or more of any class of equity interests in the Company, to report their beneficial ownership of equity interests in the Company to the SEC. Their initial reports are required to be filed using the SEC’s Form 3, and they are required to report subsequent purchases, sales and other changes using the SEC’s Form 4, which must be filed within two days of most transactions. Officers, directors and shareholders owning more than 10% of any class of equity interests in the Company are required by SEC regulations to furnish us with copies of all reports they file pursuant to Section 16(a). Based solely on our review of the copies of these reports furnished to us or written representations that no such reports were required, we believe that, during 2011, all filing requirements under 16(a) of the Exchange Act applicable to our executive officers, directors and greater that 10% shareholders were timely met.

 

23
 

 

GLENROSE INSTRUMENTS INC.

 

Item 11. Executive Compensation.

 

The Company’s Compensation Committee and Board of Directors construct policies and guidelines regarding executive compensation. As is shown in the Summary Compensation Table below, the Company’s Chief Executive Officer, Arvin H. Smith has waived his compensation in the last two years and plans to waive his compensation in the current year. Our Compensation Committee will make determinations with respect to executive compensation based on customary parameters, such as the following:

 

·ensure that the interests of our executive officers are closely aligned with those of our investors and owners;
·attract and retain highly qualified and motivated employees who can drive an enterprise to succeed in today’s competitive marketplace;
·motivate our employees to deliver high business performance;
·differentiate compensation so that it varies based on individual and team performance; and
·balance rewards for these demanding roles between short-term results and the long-term strategic decisions needed to ensure sustained business performance over time.

 

The compensation of the Company’s Chief Financial Officer is paid by American DG Energy Inc. and the Company reimburses American DG Energy. The following table sets forth information with respect to the compensation of our named executive officers as of December 31, 2011:

 

Summary Compensation Table

 

           Option   All other     
Name and principal position  Year   Salary ($)   awards ($)   compensation ($)   Total ($) 
                     
Arvin H. Smith (1)   2011    -    -    -    - 
Chief Executive Officer   2010    -    -    -    - 
                          
Dr. Richard Chapman   2011    79,997    -    -    79,997 
Executive Vice President & COO   2010    83,074    -    -    83,074 
                          
Dr. Shelton Clark   2011    140,107    -    -    140,107 
Vice President, Services   2010    128,685    -    -    128,685 
                          
Anthony S. Loumidis   2011    117,016    -    -    117,016 
Chief Financial Officer & Treasurer   2010    90,475    -    -    90,475 

 

 

 

(1)Arvin H. Smith has waived his salary, bonus and any other compensation in 2011 or 2010, and plans to waive his salary, bonus and any other compensation in 2012.

 

Outstanding Equity Awards at Fiscal Year-End

 

The following table sets forth information with respect to outstanding equity awards held by our named executive officers as of December 25, 2011. No stock option awards or other equity awards were granted in 2011 or 2010. Our named executive officers did not exercise any options during the fiscal year ended December 25, 2011.

 

   No. of securities   No. of securities         
   underlying   underlying         
   unexercised   unexercised   Option   Option 
   options (#)   options (#)   exercise   expiration 
Name  exercisable (1)   unexercisable   price ($)   date 
                 
Arvin H. Smith   -    -    -    - 
Dr. Richard Chapman   15,000    3,000   $7.00    11/13/2014 
Dr. Shelton Clark   25,000    5,000   $7.00    11/13/2014 
Anthony S. Loumidis   25,000    5,000   $7.00    11/13/2014 

 

 

  

(1)All of the common stock options included in this Outstanding Equity Awards at Fiscal Year-End table vest in equal installments over a period of 5 years from the date of the grant, which was November 13, 2007.

 

24
 

 

GLENROSE INSTRUMENTS INC.

  

Employment contracts and termination of employment and change-in-control arrangements

 

None of our executive officers has an employment contract or change-in-control arrangement.

 

Director Compensation

 

Since January 1, 2007, each director who is not also one of our employees receives an annual fee of $2,000. Non-employee directors are eligible to receive stock options under our equity incentive plan. We reimburse all of our non-employee directors for reasonable travel and other expenses incurred in attending board of directors and committee meetings. The following table sets forth information with respect to director compensation for the fiscal year ended December 25, 2011:

 

   Fees earned or   Stock   All Other     
Name  paid in cash ($)   awards ($)   compensation ($)   Total ($) 
                 
John N. Hatsopoulos   -    -    -    - 
Arvin H. Smith   -    -    -    - 
Robert Aghababian   2,000    -    -    2,000 
Barry S. Howe   2,000    -    -    2,000 
William J. Zolner   2,000    -    -    2,000 

 

401(k) Plan and other benefit plans

 

Our retirement plan, which we refer to as the 401(k) plan, is qualified under Section 401 of the Internal Revenue Code of 1986, as amended, or the Code. Our employees may elect to reduce their current compensation by an amount no greater than the statutorily prescribed annual limit and may have that amount contributed to the 401(k) plan. We may make matching or additional contributions to the 401(k) plan in amounts to be determined annually by us. To date, we have not made any contributions to the 401(k) plan.

 

We currently maintain two defined contribution 401(k) plans within Eberline Services. Additionally, employees of the Hanford Reservation site are covered by a multi-employer, defined benefit plan that is not administered by us.

 

Eberline Services’ employees are eligible to participate in the 401(k) plan immediately. Participants may elect to contribute up to 100% of their compensation to the 401(k) Plans, subject to Internal Revenue Service annual limitations. Eberline Services makes discretionary matching contributions of up to 4.5% of a participant’s compensation, depending on deferral amount. During 2008, the Company merged the Lionville 401(k) plan into the Eberline Services plan. Contributions for Lionville employees are included in the Eberline Services contribution disclosure. For the years ended December 25, 2011 and December 26, 2010, Eberline Services contributed approximately $222,903 and $285,199, respectively.

 

Certain employees of ESHI are eligible to participate in a multi-employer, defined benefit plan (Hanford Multi-Employer Pension Plan EIN# 90-0501441) or the Plan. The Plan is administered by Mission Support Alliance, LLC on behalf of eligible, participating companies via the Hanford Pension and Savings Plans Committee. The Plan is funded by participating companies on a payroll-by-payroll basis and/or in a lump-sum annual contribution as actuarially computed by the Plan administrator. We expense the computed expense amounts annually. Under the terms and conditions of the Plan, individual companies assume no liability for future pension or benefit costs associated with the Plan. The government reimburses us for all pension related costs as a direct project cost. For the years ended December 25, 2011 and December 26, 2010, the total expense was $942,369 and $787,795, respectively. The amounts represented less than five percent of the total Plan contributions during each year respectively. As of December 25, 2011, the Plan was not subject to a funding improvement Plan. As of December 25, 2011, the Plan was funded at an amount greater than 80% of future benefits. For the years ending December 25, 2011 and December 26, 2010, 157 and 160 employees participated in the Plan respectively. Additional information is publically available in the Plan’s annual Form 5500 filing.

 

Additionally, ESHI employees are eligible to participate in a traditional, employer-sponsored 401(k) plan also administered by Fluor Hanford, Inc. For the years ended December 25, 2011, and December 26, 2010, employer contributions were $815,030 and $653,168, respectively.

 

25
 

 

GLENROSE INSTRUMENTS INC.

 

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

 

The GlenRose Partnership L.P., and the holder of 3,000,000 shares of common stock of the Company, dissolved effective as of December 31, 2007. Upon dissolution, the GlenRose Partnership L.P. distributed all of the common stock of the Company that it owned to its partners. The partners of the GlenRose Partnership L.P. included certain of the Company’s officers and directors. The following table gives effect to such distribution and sets forth information with respect to the beneficial ownership of our common stock as of March 22, 2012, for:

 

each of our executive officers and directors;
all of our executive officers and directors as a group; and
any other person known by us to be a beneficial owner of more than 5% of our outstanding common stock.

 

Beneficial ownership is determined in accordance with the rules of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities and include ordinary shares issuable upon the exercise of stock options that are immediately exercisable or exercisable within 60 days. Except as otherwise indicated, all persons listed below have sole voting and investment power with respect to the shares beneficially owned by them, subject to applicable community property laws. The information is not necessarily indicative of beneficial ownership for any other purpose.

 

The following table sets forth certain information with respect to the beneficial ownership of the Company's voting securities by (i) any person (including any “group” as set forth in Section 13(d)(3) of the Exchange Act), known by us to be the beneficial owner of more than 5% of any class of our voting securities, (ii) each director, (iii) each of the named executive officers, and (iv) all of our current directors and executive officers as a group. The percentages in the following table are based on 3,112,647 shares of common stock issued and outstanding as of March 22, 2012.

 

   Number of   % 
   Shares   of Shares 
Name and address of  Beneficially   Beneficially 
beneficial owner (1)  Owned   Owned 
         
5% Stockholders:          
Arvin H. Smith (2)   513,954    16.51%
John N. Hatsopoulos (3)   513,954    16.51%
Phillip Frost, M.D. (4)   500,106    16.07%
George N. Hatsopoulos (5)   513,954    16.51%
Kenmare (6)   301,324    9.68%
Ralph Wanger Trust (7)   256,977    8.26%
WHI Private Equity Managers Fund LLC (8)   250,053    8.03%
           
Directors & Officers:          
Arvin H. Smith (2)   513,954    16.51%
John N. Hatsopoulos (3)   513,954    16.51%
Dr. Richard Chapman (9)   24,503    0.78%
Dr. Shelton Clark (10)   20,000    0.64%
Anthony S. Loumidis (11)   20,000    0.64%
Robert Aghababian   -    0.00%
Barry S. Howe   -    0.00%
William J. Zolner   -    0.00%
All executive officers and directors as a group (8 persons)   1,092,411    34.52%

 

 

 

(1)The address of the officers and directors listed in the table above is: c/o GlenRose Instruments Inc., 45 First Avenue, Waltham, Massachusetts, 02451.
(2)Includes: 513,954 shares of common stock held by the Arvin Herley & Wynona Lowe Smith, TTEES F/T Smith Living Trust, a Texas trust whose trustees are Mr. Smith and his wife, Wynona Smith, each of whom share voting power and investment power, and beneficiaries of that trust are members of Mr. and Mrs. Smith’s family.
(3)Includes: 513,954 shares of common stock held by John Hatsopoulos and his wife, Patricia Hatsopoulos, as joint tenants with rights of survivorship, each of whom share voting and investment power.
(4)Includes: (a) 500,106 shares of common stock held by Dr. Philip Frost with an address of 4400 Biscayne Boulevard, Miami, Florida 33137.

 

26
 

 

GLENROSE INSTRUMENTS INC.

 

(5)Includes: 513,954 shares of common stock held by George Hatsopoulos and his wife, Daphne Hatsopoulos, as joint tenants with rights of survivorship, each of whom share voting and investment power, with an address of 233 Tower Road, Lincoln, Massachusetts 02773.
(6)Includes 235,756 shares beneficially owned by Kenmare Fund I, L.P. and 65,568 shares beneficially owned by Kenmare Offshore, Ltd. Based on a Schedule 13G filed with the SEC on February 14, 2008, the members of the group are Kenmare Fund I, L.P., Kenmare Offshore, Ltd., Kenmare Capital Partners, LLC, Kenmare Offshore Management, LLC, and Mark McGrath, each with an address of 712 Fifth Avenue, New York, New York 10019.
(7)Includes 256,977 shares held by the Ralph Wanger Revocable Trust, an Illinois trust whose sole trustee is Ralph Wanger. Mr. Wanger has sole voting power and sole dispositive power with respect to the shares held by the Ralph Wanger Revocable Trust, with an address of 191 North Wacker Drive, Chicago, Illinois 60606.
(8)Includes 250,053 shares directly held by WHI Private Equity Managers Fund LLC, whose sole manager is William Harris Investors, Inc., and who may therefore be deemed to have voting and/or dispositive power over the shares. Michael Resnick is the only officer of William Harris Investors, Inc. who has sole voting power and sole dispositive power (acting through William Harris Investors, Inc.) with respect to the shares held by WHI Private Equity Managers Fund LLC, with an address of 191 North Wacker Drive, Chicago, Illinois 60606.
(9)Includes: (a) 12,503 shares of common stock; and (b) options to purchase 15,000 shares of common stock of which 12,000 are exercisable within 60 days of March 22, 2012.
(10)Includes options to purchase 25,000 shares of common stock of which 20,000 are exercisable within 60 days of March 22, 2012.
(11)Includes options to purchase 25,000 shares of common stock of which 20,000 are exercisable within 60 days of March 22, 2012.

 

2005 Stock Option and Incentive Plan

 

The Company’s 2005 Stock Option and Incentive Plan, or the Stock Plan, was adopted by the Company in September 2005. The Stock Plan provides for the grant of stock-based awards to employees, officers and directors of, and consultants or advisors to the Company and its subsidiaries. Under the Stock Plan, the Company may grant options that are intended to qualify as incentive stock options within the meaning of Section 422 of the Code, options not intended to qualify as incentive stock options (non-statutory options), restricted stock and other stock-based awards. Incentive stock options may be granted only to employees of the Company. A total of 700,000 shares of common stock may be issued upon the exercise of options or other awards granted under the Stock Plan. The maximum number of shares with respect to which awards may be granted to any employee under the Stock Plan shall not exceed 25% of that number.

 

The Stock Plan is administered by our board of directors and our Compensation Committee. Subject to the provisions of the Stock Plan, our board of directors and our Compensation Committee each has the authority to select the persons to whom awards are granted and determine the terms of each award, including the number of shares of common stock subject to the award. Payment of the exercise price of an award may be made in cash, in a “cashless exercise” through a broker, or if the applicable stock option agreement permits, shares of common stock or by any other method approved by our board of directors or Compensation Committee. Unless otherwise permitted by the Company, awards are not assignable or transferable except by will or the laws of descent and distribution.

 

Upon the consummation of an acquisition of the business of the Company, by merger or otherwise, our board of directors shall, as to outstanding awards (on the same basis or on different bases as our board of directors shall specify), make appropriate provision for the continuation of such awards by the Company or the assumption of such awards by the surviving or acquiring entity and by substituting on an equitable basis for the shares then subject to such awards either (a) the consideration payable with respect to the outstanding shares of common stock in connection with the acquisition, (b) shares of stock of the surviving or acquiring corporation or (c) such other securities or other consideration as our board of directors deems appropriate, the fair market value of which (as determined by our board of directors in its sole discretion) shall not materially differ from the fair market value of the shares of common stock subject to such awards immediately preceding the acquisition. In addition to or in lieu of the foregoing, with respect to outstanding stock options, our board of directors may, on the same basis or on different bases as our board of directors shall specify, upon written notice to the affected optionees, provide that one or more options then outstanding must be exercised, in whole or in part, within a specified number of days of the date of such notice, at the end of which period such options shall terminate, or provide that one or more options then outstanding, in whole or in part, shall be terminated in exchange for a cash payment equal to the excess of the fair market value (as determined by our board of directors in its sole discretion) for the shares subject to such options over the exercise price thereof. Unless otherwise determined by our board of directors (on the same basis or on different bases as our board of directors shall specify), any repurchase rights or other rights of the Company that relate to a stock option or other award shall continue to apply to consideration, including cash, that has been substituted, assumed or amended for a stock option or other award pursuant to these provisions. The Company may hold in escrow all or any portion of any such consideration in order to effectuate any continuing restrictions.

 

27
 

 

GLENROSE INSTRUMENTS INC.

 

Our board of directors may at any time provide that any stock options shall become immediately exercisable in full or in part, that any restricted stock awards shall be free of some or all restrictions, or that any other stock-based awards may become exercisable in full or in part or free of some or all restrictions or conditions, or otherwise realizable in full or in part, as the case may be.

 

Our board of directors or our Compensation Committee may, in its sole discretion, amend, modify or terminate any award granted or made under the Stock Plan, so long as such amendment, modification or termination would not materially and adversely affect the participant.

 

Equity Compensation Plans

 

As discussed above, our board of directors and stockholders have adopted the above Stock Plan and reserved 700,000 shares of our common stock for issuance thereunder. In 2007, the Company granted nonqualified options to purchase 230,000 shares of the common stock to 44 employees at $7.00 per share that vest over 5 years. In addition, in 2007 the Company made grants of restricted stock to three of its directors by permitting them to purchase an aggregate of 15,000 shares of common stock at a price of $0.01 per share. No stock options or restricted stock awards were issued in 2011 or 2010. The following table sets forth information with respect to our securities authorized for issuance under the Stock Plan as of December 25, 2011:

 

   No. of Securities       Number of securities remaining 
   to be issued upon   Weighted average   available for future issuance 
   exercise of   exercise price of   under equity compensation plans 
   outstanding options,   outstanding options,   excluding securities reflected in 
Plan Category  warrants and rights   warrants and rights   second column 
             
Equity compensation plans approved by security holders (1)   168,000   $7.00    517,000 
               
Equity compensation plans not approved by security holders   -   $-    - 
Total   168,000   $7.00    517,000 

 

 

 

(1)Includes 168,000 shares of common stock issued upon exercise of stock options at an exercise price of $7.00 per share and does not include 10,000 shares of restricted common stock issued to the Company’s directors at $0.01 per share.

 

Item 13. Certain Relationships and Related Transactions, and Director Independence.

 

Related Person Transactions

 

On July 25, 2008, the Company entered into subscription agreements with four investors for the sale of convertible debentures in the aggregate principal amount of $14,875,000. The primary investor was Blum Strategic Partners IV, L.P., who subscribed for $12,000,000 of the debentures. Additional investors included John N. Hatsopoulos, the Company’s Chairman of the board, Arvin H. Smith, the Company’s President and Chief Executive Officer, and Philip Frost M.D., a holder of more than 10% of the outstanding equity securities of the Company immediately prior to the sale of the debentures, who subscribed for $2,875,000 of debentures by exchanging promissory notes of the Company for the debentures. The debentures bear interest at 4%, payable quarterly in cash, and mature on July 25, 2013. The debentures are convertible at the option of the holder at any time into shares of common stock at an initial conversion price equal to $7.00 per share. In connection with the transaction, the Company appointed John H. Park to the Company’s board of directors. Ladenburg Thalman & Co., Inc., a registered broker-dealer, acted as placement agent on a best efforts basis for the sale of the Company’s debentures. In connection with the transaction, the Company paid the placement agent a cash fee of $600,000 which is amortized monthly over the life of the debentures and classified as interest expense.

 

In August of 2010, the Company redeemed $10,000,000 principal amount of the convertible debentures from four investors on a pro-rata basis. At December 26, 2010, the remaining balance on the convertible debentures was $4,875,000. In January 2011, the Company redeemed an additional $575,000 principal amount of the remaining balance on a pro-rata basis.

 

28
 

 

GLENROSE INSTRUMENTS INC.

 

American DG Energy Inc., or American DG Energy, EuroSite Power Inc., or EuroSite Power, Tecogen Inc., or Tecogen and Ilios Inc. or Ilios, are affiliated companies by virtue of common ownership. Specifically, John N. Hatsopoulos who is the Chairman of the Company is: (a) the Chief Executive Officer and director of American DG Energy and holds 12.2% of the company’s common stock, (b) the Chairman of the Board and director of EuroSite Power and holds 0.1% of the company’s common stock, (c) the Chief Executive Officer and director of Tecogen and holds 27.6% of the company’s common stock and (d) a director of Ilios and holds 7.3% of the company’s common stock. Dr. George N. Hatsopoulos, who is John N. Hatsopoulos’ brother, is: (a) a director of American DG Energy and holds 14.7% of the company’s common stock, (b) an investor in EuroSite Power and holds 0.3% of the company’s common stock, (c) a director of Tecogen and holds 26.2% of the company’s common stock and (d) an investor in Ilios and holds 2.9% of the company’s common stock.

 

Director Independence

 

The Company requires a majority of its board of directors to be “independent” as defined by Item 407(a) of Regulation S-K under the Securities Act of 1933 and the Exchange Act, including, in the judgment of our board of directors, the requirement that such directors have no material relationship with us. Our board of directors has determined that Messrs. Aghababian, Howe and Zolner are “independent” in accordance with Item 407(a) of Regulation S-K by applying the NASDAQ standards for independence. Each of these directors has no relationship with the Company, other than any relationship that is categorically not material under the Company’s guidelines and other than compensation for services as a director as disclosed in this Annual Report on Form 10-K. For a discussion of committee member independence see “Item 10. Directors, Executive Officer and Corporate Governance” of this Annual Report on Form 10-K.

 

Item 14. Principal Accountant Fees and Services.

 

The following table summarizes fees billed to the Company by McGladrey & Pullen, LLP, for professional services rendered for the period ended December 25, 2011 and December 26, 2010, respectively:

 

   2011   2010 
Audit fees  $130,500   $100,700 
Audit-related fees   -    - 
Tax fees   -    - 
All other fees   -    - 
   $130,500   $100,700 

  

Audit Fees. The audit fees consist of aggregate fees billed for each of the last two fiscal years for professional services rendered by the audit of our annual consolidated financial statements and review of the interim consolidated financial statements included in quarterly reports.

 

Audit-Related Fees. The audit-related fees consist of aggregate fees billed in each of the last two fiscal years for assurance and related services reasonably related to the performance of the audit or review of our consolidated financial statements and are not reported under “Audit Fees”.

 

Tax Fees. Tax fees consist of aggregate fees billed in each of the last two fiscal years for professional services for tax compliance, tax advice and tax planning. These services included assistance regarding federal and state tax compliance, and tax audit defense.

 

All Other Fees. Fees that are billed in each of the last two fiscal years for professional services rendered in connection with this Annual Report on Form 10-K are included in all other fees.

 

Audit Pre-Approval of Policies and Procedures

 

The Audit Committee’s current policy is to pre-approve all audit and permissible non-audit services provided by our independent auditors. These services may include audit services, audit related services, tax services and other services. The Audit Committee may also pre-approve particular services on a case-by-case basis.

 

Audit Committee Approval of Fees

 

Our Audit Committee approved all audit-related fees listed above provided by McGladrey & Pullen, LLP, to us during the year ended December 25, 2011.

 

29
 

 

GLENROSE INSTRUMENTS INC. 

 

PART IV

 

Item 15. Exhibits and Financial Statement Schedules.

 

(a)Index To Financial Statements and Financial Statements Schedules:

 

Report of Independent Registered Public Accounting Firm

 

Consolidated Balance Sheets as of December 25, 2011 and December 26, 2010

 

Consolidated Statements of Income for the years ended December 25, 2011 and December 26, 2010

 

Consolidated Statements of Stockholders’ Equity for the years ended December 25, 2011 and December 26, 2010

 

Consolidated Statements of Cash Flows for the years ended December 25, 2011 and December 26, 2010

 

Notes to Consolidated Financial Statements

 

All other schedules for which provision is made in the applicable accounting regulations of the SEC are not required under the related instructions, or are inapplicable, and therefore have been omitted.

 

30
 

 

 GLENROSE INSTRUMENTS INC. 

 

(b)Exhibits:

 

Exhibit
Number

  Description
     
3.1   Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company’s Form 10, as amended, originally filed with the Securities and Exchange Commission on November 17, 2006).
     
3.2   By-laws (incorporated by reference to the Company’s Form 10, as amended, originally filed with the Securities and Exchange Commission on November 17, 2006).
     
4.1   Form of 4% Convertible Debenture due 2013, as amended, (incorporated by reference to the Company’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on July 27, 2010).
     
10.1   Form of Subscription Agreement (incorporated by reference to the Company’s Form 8-K, filed with the Securities and Exchange Commission on July 29, 2008).
     
10.2   Form of Investor Rights Agreement (incorporated by reference to the Company’s Form 10-Q, filed with the Securities and Exchange Commission for the quarter ended June 29, 2008).
     
10.3*   Promissory note of Eberline Services, Inc. issued to Arvin Smith dated as of January 1, 2005 (incorporated by reference to the Company’s Form 10, as amended, originally filed with the Securities and Exchange Commission on November 17, 2006).
     
10.4*   Promissory note of Eberline Services, Inc. issued to John N. Hatsopoulos and Patricia Hatsopoulos dated as of January 1, 2005 (incorporated by reference to the Company’s Form 10, as amended, originally filed with the Securities and Exchange Commission on November 17, 2006).
     
10.5*   Promissory note of Eberline Services, Inc. issued to Arvin Smith dated as of December 17, 2007 (incorporated by reference to the Company’s Form 10-K, as amended, originally filed with the Securities and Exchange Commission on March 31, 2008 for the year ended December 28, 2008).
     
10.6*   GlenRose Instruments Inc. 2005 Stock Option and Incentive Plan (incorporated by reference to the Company’s Form 10, as amended, originally filed with the Securities and Exchange Commission on November 17, 2006).
     
10.7   Lease Agreement between J.W. Gibson Construction Company and Eberline Analytical Corp. dated October 24, 2000 (incorporated by reference to the Company’s Form 10, as amended, originally filed with the Securities and Exchange Commission on November 17, 2006).
     
10.8   Lease Agreement between G-C-T Corporation and Lionville Laboratories, Inc. dated September 23, 2004 (incorporated by reference to the Company’s Form 10, as amended, originally filed with the Securities and Exchange Commission on November 17, 2006).
     
10.9   Lease Agreement between Eberline Services, Inc. and First Industrial Pennsylvania LP., dated June 1, 2008 (incorporated by reference to the Company’s Form 10-Q, filed with the Securities and Exchange Commission for the quarter ended June 29, 2008).
     
10.10   Agreement between Washington Closure Hanford, LLC and Eberline Services Hanford, Inc. (incorporated by reference to the Company’s Form 10, as amended, originally filed with the Securities and Exchange Commission on November 17, 2006).
     
10.11   Subcontract Agreement No. 69899-000-09 between Los Alamos National Security, LLC, and Eberline Services, Inc. dated November 4, 2008 (incorporated by reference to the Company’s Form 10-K filed with the Securities and Exchange Commission on March 27, 2009).
     
10.12*   Form of Restricted Stock Purchase Agreement (incorporated by reference to the Company’s Form 10-K filed with the Securities and Exchange Commission on March 27, 2009).

 

31
 

 

GLENROSE INSTRUMENTS INC.

 

10.13*   Form of Stock Option Agreement Under 2005 Stock Option and Incentive Plan (incorporated by reference to the Company’s Form 10-K filed with the Securities and Exchange Commission on March 27, 2009).
     
10.14   Letter Agreement with Raymond James & Associates, Inc. dated March 3, 2011.
     
14.1   Code of Business Conduct and Ethics (incorporated by reference to the Company’s Form 10, as amended, originally filed with the Securities and Exchange Commission on November 17, 2006).
     
21.1   List of subsidiaries (incorporated by reference to the Company’s Form 10, as amended, originally filed with the Securities and Exchange Commission on November 17, 2006).
     
23.1#   Consent of McGladrey & Pullen, LLP.
     
31.1#   Rule 13a-14(a) Certification of Chief Executive Officer.
     
31.2#   Rule 13a-14(a) Certification of Chief Financial Officer.
     
32.1   Section 1350 Certifications of Chief Executive Officer and Chief Financial Officer (Furnished herewith).
     
101.1   The following materials from the Company's Annual Report on Form 10-K for the year ended December 25, 2011 formatted in XBRL (eXtensible Business Reporting Language): (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements of Operations, (iii) the Consolidated Statements of Stockholders' Equity, (iv) the Consolidated Statements of Cash Flows, and (v) related notes to these financial statements, tagged as blocks of text and in detail (Furnished herewith).

 

 

 

#Filed herewith.
*Management contract or compensatory plan or arrangement.

 

32
 

 

GLENROSE INSTRUMENTS INC.

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  GLENROSE INSTRUMENTS INC.
  (Registrant)
   
  By: /s/ Arvin H. Smith
  Chief Executive Officer and President
  (Principal Executive Officer)
   
  By: /s/ Anthony S. Loumidis
  Chief Financial Officer, Treasurer and Secretary
  (Principal Financial Officer)

 

Dated: March 23, 2012

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacity and on the dates indicated.

 

Signature   Title   Date
         
/s/ John N. Hatsopoulos   Chairman of the Board and Director   March 23, 2012
John N. Hatsopoulos        
         
/s/ Arvin H. Smith   Director, President and Chief Executive Officer   March 23, 2012
Arvin H. Smith   (Principal Executive Officer)    
         
/s/ Anthony S. Loumidis   Chief Financial Officer, Treasurer and Secretary   March 23, 2012
Anthony S. Loumidis   (Principal Financial & Accounting Officer)    
         
/s/ Robert Aghababian   Director   March 23, 2012
Robert Aghababian        
         
/s/ Barry S. Howe   Director   March 23, 2012
Barry S. Howe        
         
/s/ William J. Zolner   Director   March 23, 2012
William J. Zolner        

 

33
 

 

GLENROSE INSTRUMENTS INC. 

 

Report of Independent Registered Public Accounting Firm

 

To the Board of Directors and Stockholders of

GlenRose Instruments Inc.

 

We have audited the accompanying consolidated balance sheets of GlenRose Instruments Inc. (a Delaware corporation) and subsidiaries (the “Company”) as of December 25, 2011 and December 26, 2010 and the related consolidated statements of income, changes in stockholders’ equity and cash flows for the years then ended. These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits.

 

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurances about whether the consolidated financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

 

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of the Company as of December 25, 2011 and December 26, 2010 and the results of their operations and their cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.

 

/s/ MCGLADREY & PULLEN, LLP  
   
Boston, Massachusetts  
March 23, 2012  

 

F-1
 

 

 GLENROSE INSTRUMENTS INC.

 

CONSOLIDATED BALANCE SHEETS

DECEMBER 25, 2011 AND DECEMBER 26, 2010

 

   2011   2010 
         
ASSETS          
Current Assets          
Cash and cash equivalents  $831,516   $1,669,868 
Short-term investments   12,305    12,305 
Accounts receivable (net of allowances of $24,320 and $26,120 for 2011 and 2010, respectively)   3,932,918    4,376,929 
Unbilled contract receivables   1,110,193    370,887 
Due from related party   42,858    42,858 
Supply inventory   61,758    60,271 
Prepaid expenses   163,559    97,450 
Other receivables   6,561    58,464 
Income tax receivable   -    161,356 
Deferred tax asset, current portion   290,281    280,058 
Assets held for sale   1,178,306    1,045,367 
Total current assets   7,630,255    8,175,813 
           
Property, plant and equipment, net   1,527,206    1,557,088 
           
Other assets          
Restricted assets   451,406    450,000 
Deposits   53,065    53,065 
Deferred tax asset, net of current portion   207,926    194,177 
Deferred financing costs   83,451    104,499 
Goodwill   2,740,913    2,740,913 
Total other assets   3,536,761    3,542,654 
           
TOTAL ASSETS  $12,694,222   $13,275,555 

 

The accompanying notes are integral part of these consolidated financial statements.

 

F-2
 

 

 GLENROSE INSTRUMENTS INC.

 

CONSOLIDATED BALANCE SHEETS

DECEMBER 25, 2011 AND DECEMBER 26, 2010

 

   2011   2010 
         
LIABILITIES AND STOCKHOLDERS' EQUITY          
Current liabilities          
Accounts payable  $2,228,321   $653,130 
Deferred revenue   172,697    - 
Accrued expenses   342,736    363,327 
Accrued employee-related costs   2,000,903    1,972,581 
Accrued interest, related party   -    48,750 
Term note payable, current portion   142,857    - 
Notes payable, current portion   52,116    13,978 
Due to related party   22,078    8,002 
Capital lease obligations, current portion   11,915    10,752 
Income taxes payable   283,635    18,130 
Total current liabilities   5,257,258    3,088,650 
           
Long-term liabilities          
Convertible debentures due to related parties   -    4,875,000 
Term note payable, net of current portion   821,429    - 
Note payable, net of current portion   24,619    13,634 
Capital lease obligations, net of current portion   26,613    38,527 
Deferred tax liability   524,269    427,198 
Other long-term liabilities   24,037    134,552 
Total liabilities   6,678,225    8,577,561 
           
Stockholders' equity          
Common stock ($0.01 par value; 10,000,000 shares authorized; 3,112,647 and 3,117,647 shares issued and outstanding at December 25, 2011 and December 26, 2010, respectively)   31,126    31,176 
Additional paid-in-capital   8,004,229    7,972,098 
Accumulated deficit   (2,019,358)   (3,305,280)
Total stockholders' equity   6,015,997    4,697,994 
           
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY  $12,694,222   $13,275,555 

 

The accompanying notes are integral part of these consolidated financial statements.

 

F-3
 

 

GLENROSE INSTRUMENTS INC. 

 

CONSOLIDATED STATEMENTS OF INCOME

FOR THE YEARS ENDED DECEMBER 25, 2011 AND DECEMBER 26, 2010

 

   2011   2010 
         
Revenues  $44,487,517   $40,945,262 
           
Cost of sales   39,952,210    36,735,257 
           
Gross profit from operations   4,535,307    4,210,005 
           
General and administrative expenses   2,242,090    2,316,393 
           
Operating income   2,293,217    1,893,612 
           
Other income (expense)          
Interest and other income   4,926    11,420 
Interest expense   (276,167)   (784,540)
Total other expense   (271,241)   (773,120)
           
Income from operations, before income taxes   2,021,976    1,120,492 
           
(Provision) benefit for income taxes   (736,054)   28,907 
           
Net income  $1,285,922   $1,149,399 
           
Net income per share - basic and diluted  $0.41   $0.37 
          
Weighted average shares outstanding - basic and diluted   3,102,647    3,102,647 

 

The accompanying notes are integral part of these consolidated financial statements.

 

F-4
 

 

 GLENROSE INSTRUMENTS INC.

 

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

FOR THE YEARS ENDED DECEMBER 25, 2011 AND DECEMBER 26, 2010

 

   Common Stock             
   $0.01 Par Value   Additional       Total 
   Number       Paid-in   Accumulated   Stockholders' 
   of Shares   Amount   Capital   Deficit   Equity 
                     
Balance, December 27, 2009   3,117,647   $31,176   $7,898,613   $(4,454,679)  $3,475,110 
                          
Stock-based compensation expense   -    -    73,485    -    73,485 
                          
Net income   -    -    -    1,149,399    1,149,399 
                          
Balance, December 26, 2010   3,117,647   $31,176   $7,972,098   $(3,305,280)  $4,697,994 
                          
Stock-based compensation expense   -    -    32,081    -    32,081 
                          
Cancellation of restricted stock   (5,000)   (50)   50    -    - 
                          
Net income   -    -    -    1,285,922    1,285,922 
                          
Balance, December 25, 2011   3,112,647   $31,126   $8,004,229   $(2,019,358)  $6,015,997 

 

The accompanying notes are integral part of these consolidated financial statements.

 

F-5
 

 

 

GLENROSE INSTRUMENTS INC.

 

CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE YEARS ENDED DECEMBER 25, 2011 AND DECEMBER 26, 2010

 

   2011   2010 
         
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net income  $1,285,922   $1,149,399 
Adjustments to reconcile net income to net cash provided by operating activities:          
Depreciation and amortization   518,757    431,745 
Provision for deferred income taxes   73,099    (47,037)
Amortization of deferred financing costs   21,048    325,501 
Stock-based compensation   32,081    73,485 
Bad debt expense   (1,800)   8,081 
Loss on disposal of fixed assets   -    (3,132)
Changes in operating assets and liabilities          
(Increase) decrease in:           
Accounts receivable   445,811    (1,297,023)
Restricted cash   (1,406)   (35,000)
Other receivables   51,903    (41,510)
Unbilled contract receivables   (739,306)   280,450 
Prepaid expenses   (66,109)   (25,050)
Supply inventory   (1,487)   5,204 
Assets held for sale   (132,939)   - 
Income tax receivable   161,356    23,615 
Increase (decrease) in:          
Accounts payable   1,575,191    (81,514)
Notes payable   -    27,612 
Accrued interest, related party   (48,750)   (213,972)
Due to related party   14,076    (8,543)
Deferred revenue   172,697    - 
Other long-term liabilities   (110,515)   97,809 
Other accrued liabilities   273,236    272,888 
Net cash provided by operating activities   3,522,865    943,008 
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Purchase of property and equipment   (488,875)   (338,369)
Proceeds from the sale of short-term investments   -    10,048,611 
Selling costs on assets held for sale   -    17,955 
Net cash (used in) provided by investing activities   (488,875)   9,728,197 
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Redemption of convertible debentures   (4,875,000)   (10,000,000)
Proceeds from term note payable   964,286    - 
Advance on line of credit   17,156,024    - 
Payments on line of credit   (17,156,024)   - 
Payments on notes payable   49,123    - 
Principal payments on capital lease obligations   (10,751)   (13,587)
Net cash used in financing activities   (3,872,342)   (10,013,587)
           
Net increase (decrease) in cash and cash equivalents   (838,352)   657,618 
Cash and cash equivalents, beginning of the year   1,669,868    1,012,250 
Cash and cash equivalents, end of the year  $831,516   $1,669,868 
           
Supplemental cash flow information          
Assets acquired under capital lease  $-   $40,349 
Cash paid during the year for interest  $217,801   $397,156 
Cash paid during the year for taxes  $373,400   $34,800 

  

The accompanying notes are integral part of these consolidated financial statements.

 

F-6
 

 

GLENROSE INSTRUMENTS INC.

 

Note 1 - The organization and significant accounting policies:

 

Organization

 

GlenRose Instruments Inc., a Delaware corporation, or the Company, was incorporated in September 2005 by the GlenRose Partnership L.P., or the GlenRose Partnership, a private-equity partnership with its headquarters in Waltham, Massachusetts. The Company was organized to serve as a holding company through which the GlenRose Partnership’s partners would hold the shares of Eberline Services, Inc. or Eberline Services or ESI (all of which had previously been held by the GlenRose Partnership). In order to effect such change in structure, the GlenRose Partnership entered into a stock exchange agreement with the Company in September 2005 pursuant to which all outstanding shares of Eberline Services owned by the GlenRose Partnership were exchanged for 3,000,000 shares of common stock of GlenRose Instruments. As a result of this exchange, the GlenRose Partnership owned all of the outstanding stock of the Company, and the Company owned all of the outstanding stock of its subsidiary, ESI.

 

On August 30, 2007, the Company issued 102,647 shares to a limited number of accredited investors through a private placement of common stock at a price per share of $7.00. On December 31, 2007, the limited partners and the general partner of the GlenRose Partnership dissolved the partnership and distributed the 3,000,000 shares of common stock of the Company to its limited partners in accordance with the GlenRose Partnership plan of liquidation and distribution.

 

GlenRose Instruments, through Eberline Services and its subsidiaries, provides radiological services and operates a radiochemistry laboratory network, as well as provides radiological characterization and analysis, hazardous, radioactive and mixed waste management, and facility, environmental, safety and health management. The subsidiaries of Eberline Services are Eberline Services Hanford, Inc. or ESHI, Eberline Analytical Corporation, Benchmark Environmental Corp., and Lionville Laboratory Inc., or Lionville.

 

Principles of Consolidation and Basis of Presentation

 

The accompanying consolidated financial statements include the Company and its subsidiaries. All significant intercompany transactions have been eliminated.

 

Fiscal Year

 

The Company’s fiscal year-end is the last Sunday of each calendar year. Each quarter is comprised of two four-week and one five-week period to ensure consistency in prior-year comparative analysis. The current fiscal year-end is December 25, 2011. The previous fiscal year-end was December 26, 2010.

 

Use of Estimates in Preparation of Statements

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and underlying assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

 

Concentration of Credit Risk

 

Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of highly liquid cash equivalents and trade receivables. The Company’s cash equivalents are placed with certain financial institutions and issuers. At December 25, 2011, the Company had a balance of $843,821 in cash and cash equivalents, short-term investments and restricted cash that exceeded the Federal Deposit Insurance Corporation limit of $250,000.

 

The Company performs periodic credit evaluations of its customers’ financial condition and generally does not require collateral. The Company provides for an allowance for doubtful accounts on receivable balances based upon the expected collectability of such receivables. Federal and state governments collectively account for more than 90% of environmental services and laboratory revenues for the years ended December 25, 2011 and December 26, 2010. Only two of the Company’s customers account for more than 10% of revenue and trade accounts receivable. One customer represented approximately 74% and 70% of revenue and 28% and 45% of trade accounts receivable for the years ended December 25, 2011 and December 26, 2010, respectively. The other customer represented approximately 7% and 8% of revenue and 13% and 3% of trade accounts receivable for the years ended December 25, 2011 and December 26, 2010, respectively.

 

F-7
 

 

GLENROSE INSTRUMENTS INC.

 

Fair Value of Financial Instruments

 

At December 25, 2011 the Company’s financial instruments include cash and cash equivalents, certificates of deposit, accounts receivable, accounts payable, capital lease obligations, line of credit payable, term note payable and notes payable. The recorded values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value based on their short-term nature. The fair value of capital lease obligations and notes payable is estimated at its carrying value based on current rates. The carrying value of the Company’s line of credit and term loan approximates its fair value due to its variable interest rate. Short-term investments are recorded at fair value.  See “Note 10 – Fair value measurements.”

 

Cash and Cash Equivalents

  

The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company has cash balances in certain financial institutions in amounts which occasionally exceed current federal deposit insurance limits. The financial stability of these institutions is continually reviewed by senior management. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents.

 

Restricted Assets

 

Restricted assets include certificates of deposit set aside to meet statutory requirements in the event of decommissioning activities of certain laboratory operations and are not indicative of any incurred liability.

 

Property and Equipment

 

Property and equipment are stated at cost less accumulated depreciation. Maintenance, repairs and minor renewals are expensed to operations as incurred. Major repairs and betterments, which substantially extend the useful life of the property, are capitalized. Depreciation is provided for principally on a straight-line basis in amounts sufficient to charge the cost of depreciable assets to operations over the estimated service lives of assets as follows:

 

Buildings & improvements   12 to 30 years
Computer equipment   3 years
Plant and laboratory equipment   8 to 10 years

 

Leasehold improvements are amortized using the straight-line method over the lesser of the estimated useful lives of the assets or the term of the related leases.

 

Recovery of Long-Lived Assets

 

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the remaining estimated useful life of such assets might warrant revision or that the balances may not be recoverable. If undiscounted cash flows are insufficient to recover the net book value of long-term assets further analysis is performed in order to determine the amount of the impairment. In such circumstances an impairment loss would be recorded equal to the amount by which the net book value of the assets exceeds fair value. Fair value is usually determined based on the present value of estimated expected future cash flows using a discount rate commensurate with the risks involved. No events occurred or circumstances changed at December 25, 2011, that would indicate that the remaining net book value of the Company’s long-lived assets are not recoverable.

 

Goodwill

 

Goodwill is the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. Goodwill is subject to an impairment test annually. Goodwill is also reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. The Company performs impairment testing at the reporting unit level. An impairment loss is recognized when the fair value of the discounted cash flows of the reporting unit including its tangible assets is less than the carrying value. Model assumptions are based on the Company’s projections and best estimates using appropriate and customary market participant assumptions. Changes in forecasted cash flows or the discount rate would affect the estimated fair value of the reporting unity and could result in a goodwill impairment charge in a future period.

 

At December 25, 2011, and December 26, 2010, the Company’s entire $2,740,913 goodwill balance was related to the Environmental Services segment which includes Eberline Services, ESHI and Benchmark Environmental Corp. The Analytical Laboratories goodwill was written off in prior years. No goodwill impairment was identified during the years ended December 25, 2011, and December 26, 2010.

 

F-8
 

 

GLENROSE INSTRUMENTS INC.

 

Revenue Recognition

 

Revenue for laboratory services is recognized upon completion of the services and the shipment of the related data packages to the Company’s customers. Revenue for government service contracts is recognized as the services are performed. Revenues are recognized based upon actual costs incurred plus specified fees or actual time and materials as required. The Company performs certain contracts that are audited by either the Defense Contract Audit Agency, or the DCAA, or Los Alamos National Laboratories Internal Audit. Such contracts may be subject to adjustment dependent upon such factors as provisional billing rates or other contract terminology. The Company records as revenue what it considers to be allowable costs under government service contracts. Calculations of allowable overhead and profit may also change after audits by the DCAA for cost reimbursable type contracts. Contracts are normally settled during the audit year the contract terminates performance and is submitted for closure. The Company is currently audited and settled through December 2005 for all contracts subject to review by DCAA and audited through December 2002 for contracts subject to review by the Los Alamos Internal Audit. Contracts performed after 2005 for DCAA purposes, or after 2002 for the Los Alamos Internal Audit, and are either active or have not been submitted for closure may be subject to adjustment during subsequent audits during the year they are closed and audited.

 

The Company is engaged principally in three types of service contracts with the federal government and its contractors:

 

Cost Reimbursable Contracts. Revenue from “cost-plus-fixed-fee” contracts is recognized on the basis of reimbursable contract costs incurred during the period plus an earned fee. Costs incurred for services which have been authorized and performed, but may not have been billed, are allocated with operational fringe, overhead, general and administrative expenses and fees, and are presented as Unbilled Contract Receivables on the accompanying consolidated balance sheets contained herein.

 

Time-and-Materials Contracts. Revenue from “time and material” contracts is recognized on the basis of man-hours utilized plus other reimbursable contract costs incurred during the period.

 

Fixed-Price Contracts. Revenue from “fixed-price” contracts is recognized on the percentage-of-completion method.  For fixed-price contracts, the amount of revenues recognized is that portion of the total contract amount that the actual cost expended bears to the anticipated final total cost based on current estimates of cost to complete the project (cost-to-cost method).  However, when it becomes known that the anticipated final total cost will exceed the contract amount, the excess of cost over the contract amount is immediately recognized as a loss on the contract. Recognition of profit commences on an individual project only when cost to complete the project can reasonably be estimated and after there has been some meaningful performance achieved on the project (greater than 10% complete). Changes in job performance, job conditions, and estimated profitability, including those arising from contract penalty provisions (when applicable) and final contract settlements, may result in revisions to costs and income and are recognized in the period in which the revisions are determined. Claims and change orders are not recorded and recognized until such time as they have been accepted.

 

Direct costs of contracts include direct labor, subcontractors and consultants, materials and travel. The treatment of direct costs is outlined in the Federal Acquisition Regulations. The balance of costs, including facilities costs, insurance, administrative costs, overhead labor and fringe costs, are classified as either indirect costs or general and administrative expense and are allocated to jobs as a percentage of each division’s total cost base consistent with the Company’s approved cost structure. Direct materials, direct travel, other direct costs, and minor subcontract costs are passed through to the customer at cost, with or without fee depending on contract type and/or direct cost element and are burdened with general and administrative expenses. Major subcontracts are passed through at cost, without fee and are burdened with a material handling fee. The Company is exempt from federal cost accounting standards coverage based on its size standard, but otherwise complies with applicable regulations.

 

Government Accounting System

 

The Company’s accounting system is audited periodically by the DCAA for adequacy. Contractors to the federal government are required to comply with regulations that may exceed generally accepted accounting principles. If the Company is unable to maintain an adequate accounting system, as defined by the DCAA, it could have a material impact on its ability to perform services with the federal government. The Company was last audited for adequacy in the fall of 2010, at which time its accounting system was deemed “adequate”. The Company’s accounting software is provided by Deltek, Inc. and is specific to the government contract industry.

 

F-9
 

 

GLENROSE INSTRUMENTS INC.

 

The Company is periodically audited by the DCAA for “financial capability”. If the Company was deemed financially unable to perform services, it could have a material impact on its business. The Company was last audited for financial capability in December 2006 and was deemed financially capable.

 

Accounts Receivable

 

Accounts receivable are carried at original invoice amounts less an estimate made for doubtful receivables based on a review of all outstanding amounts on a monthly basis. Management determines the allowance for doubtful accounts by identifying troubled accounts and by using historical experience applied to an aging of accounts. Accounts receivable are written off when deemed uncollectible. Recoveries of accounts receivable previously written off are recorded as a credit to bad debt expense when received.

  

Unbilled Contract Receivables

 

Costs related to work that has been completed and performed, for which revenue has been recognized but are not yet fully billed, are classified as “unbilled contract receivables.” 

 

Supply Inventory

 

Inventories are stated at the lower of cost or market, valued on a first-in, first-out basis. Inventory is reviewed periodically for slow-moving and obsolete items. As of December 25, 2011 and December 26, 2010, there were no reserves or write-downs recorded against inventory.

 

Income Taxes

 

The Company uses the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. The amount of such provisions is based on various factors, such as the amount of taxable income in the current and prior periods, and the likelihood of continued taxable income. Additionally, management is responsible for estimating the probability that certain tax assets or liabilities can and will be utilized in future periods. The Company believes it records and/or discloses such potential tax liabilities as appropriate and has reasonably estimated its income tax liabilities and recoverable tax assets.

 

Earnings per Common Share

 

The Company computes basic net income per share by dividing net income for the period by the weighted average number of shares of common stock outstanding during the period. The Company computes diluted net income per common share using the treasury stock method. For purposes of calculating diluted net income per share, the Company considers shares issuable in connection with convertible debentures and stock options to be dilutive common stock equivalents when the exercise price is less than the average market price of the common stock for the period. As of the year ended December 25, 2011, the Company excluded the impact of 178,000 anti-dilutive shares resulting from exercise of stock options, warrants and unvested restricted stock, and as of the year ended December 26, 2010, the Company excluded the impact of 884,429 anti-dilutive shares resulting from conversion of debentures and exercise of stock options, warrants and unvested restricted stock.

 

Stock Based Compensation

 

Stock based compensation cost is measured at the grant date based on the estimated fair value of the award and is recognized as an expense in the statement of income over the requisite service period. The fair value of stock options granted is estimated using the Black-Scholes option pricing valuation model. The Company recognizes compensation on a straight-line basis for each separately vesting portion of the option award. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs. Expected volatility is calculated based on the average volatility of 20 companies in the same industry as the Company. The average expected life is estimated using the simplified method for “plain vanilla” options. The simplified method determines the expected life in years based on the vesting period and contractual terms as set forth when the award is made. The Company uses the simplified method for awards of stock-based compensation since it does not have the necessary historical exercise and forfeiture data to determine an expected life for stock options. The risk-free interest rate is based on U.S. Treasury zero-coupon issues with a remaining term which approximates the expected life assumed at the date of grant. When options are exercised the Company normally issues new shares.

 

F-10
 

 

GLENROSE INSTRUMENTS INC.

 

See “Note 6 – Stockholders’ equity” for a summary of the restricted stock and stock option activity under the Company’s stock-based employee compensation plan for the year ended December 25, 2011.

 

Research and Development Costs

 

Research and development costs are expensed when incurred. Such costs are $0 for the year ended December 25, 2011 and $138,378 for the year ended December 26, 2010, and are included in the Company’s accompanying consolidated statements of income.

 

Impact of New Accounting Pronouncements

 

In September 2011, the Financial Accounting Standards Board issued an amendment to the accounting guidance for goodwill in order to simplify how companies test goodwill for impairment. The amendment permits an entity to first assess the qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test. The more-likely-than-not threshold is defined as having a likelihood of more than 50 percent. If, after assessing the totality of events or circumstances, an entity determines it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing the two-step impairment test is unnecessary. The amendment is effective for annual and interim goodwill impairment tests performed for fiscal years beginning after December 15, 2011. Early adoption is permitted. The Company elected not to early adopt. The Company does not expect the adoption of this accounting pronouncement to have a material effect on its financial statements when implemented.

 

The Company does not expect the impact of recently issued accounting pronouncements to have a material impact on the Company’s results of operations, financial position or cash flows.

 

Reclassifications

 

Certain prior period balances have been reclassified to conform with current period presentation.

 

Note 2 – Property plant and equipment:

 

Property, plant and equipment consist of the following as of December 25, 2011 and December 26, 2010:

 

   2011   2010 
         
Land  $267,814   $267,814 
Buildings and improvements   984,326    991,655 
Machinery and equipment   5,554,970    5,143,096 
Assets under capital lease   97,120    97,120 
Leasehold improvements   567,452    613,936 
    7,471,682    7,113,621 
Less: accumulated depreciation   (5,944,476)   (5,556,533)
Net property, plant and equipment  $1,527,206   $1,557,088 

 

Depreciation expense for the years ended December 25, 2011 and December 26, 2010 was $518,757 and $431,745, respectively.

 

The Company owns property in Albuquerque, New Mexico. In 2009, the Company entered into an agreement, subject to closing conditions, with a buyer to sell the property for approximately $1.9 million. At December 25, 2011, $507,700 in land, $2,265,764 in buildings and improvements less $1,916,926 in accumulated depreciation is classified as “Assets held for sale” on the Company’s balance sheet. The assets held for sale balance of $1,178,306 also includes selling costs incurred to date of $37,477 and an accrual of $284,291 towards decommissioning of the site. In 2010, the Company submitted a detailed site assessment of the facility to the New Mexico Environmental Department, or NMED, as part of the closure process which was approved in June 2011. The Company characterized and classified all radiological waste associated with the facility and all waste was crated and packaged for disposal in 2010. In January 2011, the Company applied for a shipment permit to transfer the remaining waste to an appropriate facility, which was shipped during the fourth quarter. The Company is currently communicating with NMED on the report in preparation for the demolition of the building. The Company believes that it has adequately accrued for decommissioning of the site however it is possible that additional funds may be required as the Company commences the actual demolition process. The Company expects to complete the sale in 2012.

 

F-11
 

 

GLENROSE INSTRUMENTS INC.

 

Note 3 – Debt:

 

Related Party Debt

 

On July 25, 2008, the Company entered into subscription agreements with four investors for the sale of convertible debentures in the aggregate principal amount of $14,875,000. The primary investor was Blum Strategic Partners IV, L.P., who subscribed for $12,000,000 of the debentures. Additional investors included John N. Hatsopoulos, the Company’s Chairman of the Board, Arvin H. Smith, the Company’s President and Chief Executive Officer, and Philip Frost M.D., a holder of more than 10% of the outstanding equity securities of the Company immediately prior to the sale of the debentures, who subscribed for $2,875,000 of debentures by exchanging existing promissory notes of the Company for the debentures. The debentures carried interest at 4%, payable quarterly in cash, and matured on July 25, 2013. The debentures were convertible at the option of the holder at any time into shares of common stock at a conversion price equal to $7.00 per share.

 

On July 23, 2010, the holders of the outstanding principal amount of the Company’s convertible debentures, agreed to amend the debenture agreements to eliminate subsections (i) and (ii) of Section 6(a) of the debentures. With this amendment the holders gave the Company the option to redeem any portion of the debentures by written notice to the holders; provided that a redemption notice is delivered by the Company and be received by the holder of the debentures at least ten (10) trading days but not more than thirty (30) trading days prior to the date of the redemption. In connection with the amendment described above, the Company redeemed $10,000,000 on August 9, 2010, $575,000 on January 13, 2011, and $500,000 on March 31, 2011.

 

On July 1, 2011, the Company redeemed the outstanding amount of the convertible debentures with Blum Strategic Partners IV, L.P., in the principal amount of $3,065,546, plus accrued interest. In connection with that transaction, the Company entered into a $500,000 Demand Note Agreement with John N. Hatsopoulos, the Company’s Chairman of the Board, and into a $1,500,000 Demand Note Agreement with Arvin H. Smith, the Company’s Chief Executive Officer. Both demand note agreements accrued interest at the rate of 4.50% per year.

 

Other Debt

 

On August 31, 2011, the Company entered into a line of credit agreement with Wells Fargo Bank for a $5,000,000 credit facility. The facility included a $1,000,000 term real-estate note, or Term Note, with a 7 year straight line amortization, at Libor plus 3.5%, and up to $4,000,000 in a revolving line of credit, or Line of Credit, for 5 years, at Libor plus 3.5%, based on a borrowing base of the Company’s trade receivables subject to certain adjustments. At December 25, 2011, the interest rate on the Line of Credit was 4.05%.

 

The Term Note and Line of Credit are payable by Eberline Services Inc., Eberline Services Hanford Inc., Eberline Analytical Laboratory Inc., and Lionville Laboratory Inc., subsidiaries of the Company. The Term Note is secured by the Company’s real estate assets which are included in fixed assets which at December 25, 2011 had a net book value of $1,527,206. The Line of Credit is secured by the Company’s trade receivables. The undrawn portion of the Line of Credit at December 31, 2011 was $4,000,000. The loan is also subject to various financial statement covenants including EBITDA, book value, and fixed charge coverage ratio. On August 31, 2011, the Company borrowed $1,000,000 against the Term Note and $1,000,000 against the Line of Credit and used the proceeds to redeem the remaining balance of the convertible debentures and pay down the Demand Note Agreements with John N. Hatsopoulos and Arvin H. Smith.

 

In December 2010, the Company entered into a finance agreement with Ford Motor Credit. At December 25, 2011 the outstanding balance with Ford Motor Credit was $76,735 and it is classified on the Company’s balance sheet as Notes payable current and Notes payable long-term.

 

As of December 25, 2011, there were no convertible debentures outstanding and the Demand Note Agreements were paid in full. As of December 25, 2011, the balance outstanding on the Term Note was $964,286 and the balance outstanding on the revolving line of credit was $0.

 

F-12
 

 

GLENROSE INSTRUMENTS INC.

 

The Company’s debt at December 25, 2011 and December 26, 2010 was as follows:

 

   2011   2010 
         
Long-term debt          
Convertible debentures  $-   $4,875,000 
Wells Fargo term note   964,286    - 
Ford Motor credit   76,735    27,612 
Capital lease obligations   38,528    49,279 
   $1,079,549   $4,951,891 
           
Less current portion          
Convertible debentures  $-   $- 
Wells Fargo term note   142,857    - 
Ford Motor credit   52,116    13,978 
Capital lease obligations   11,915    10,752 
   $206,888   $24,730 
           
Total long-term debt          
Convertible debentures  $-   $4,875,000 
Wells Fargo term note   821,429    - 
Ford Motor credit   24,619    13,634 
Capital lease obligations   26,613    38,527 
   $872,661   $4,927,161 

 

Annual principal payments on long-term debt at December 25, 2011 were as follows:

 

Years Ending December 31,  Amount 
     
2012  $206,888 
2013   180,682 
2014   152,135 
2015   146,986 
2016   142,858 
2017 and thereafter   250,000 
Total  $1,079,549 

 

Note 4 – Commitments and contingencies:

 

The Company and its subsidiaries lease facilities and equipment under various operating leases. Future minimum rental commitments for long-term, non-cancelable operating leases at December 25, 2011 were as follows:

 

Summary of Lease Obligations:

 

   2012   2013   2014   2015   Totals 
                     
Facilities  $309,504   $139,655   $49,128   $12,282   $510,569 
Equipment   15,217    15,217    10,144    4,227    44,805 
   $324,721   $154,872   $59,272   $16,509   $555,374 

 

For the years ended December 25, 2011 and December 26, 2010, rent expense was $343,617 and $378,728, respectively.

 

F-13
 

 

GLENROSE INSTRUMENTS INC.

 

The Company performs services under numerous subcontract agreements on cost-reimbursable contracts with the federal government. During the period from 1998 to 2003, the Company was party to a subcontract agreement with Johnson Control Northern New Mexico, or JCNNM, to provide services to Los Alamos on a cost-reimbursable basis. On May 14, 2007, the Company received notification from IAP-Northern New Mexico, or IAPNNM, the successor corporation to JCNNM, that the results of a Los Alamos audit for the period ending in 2003 determined that certain costs previously claimed and billed by the Company were subsequently deemed unallowable or otherwise not reimbursable. IAPNNM requested that the Company reimburse the amount of $321,836 that was paid to the Company during the subject time period. In January 2009, the Company protested the Los Alamos audit results claiming they were inaccurate and requested to resubmit a claim for the subject contract. The Los Alamos audit team agreed to review the audit results and adjust the claim as needed. Management believes that the Company will prevail in this decision and has therefore not provided a specific reserve for this claim. In the event it is determined that the Company has to reimburse such amount in full, the resultant cost could materially affect its results of operations.

 

The Company is not currently a party to any material litigation and is not aware of any pending or threatened litigation against it that could have a material adverse effect on its business, operating results or financial condition.

 

Note 5 - Capital leases:

 

The Company periodically leases laboratory equipment under capital lease agreements. The lease terms are typically from three to five years, depending on the type of equipment. The leased equipment typically has a bargain purchase price, and qualifies for treatment as a capital lease. For book purposes, the assets are amortized over their estimated useful lives.

 

Assets under capital lease as of December 25, 2011 and December 26, 2010 were as follows:

 

   2011   2010 
Equipment  $97,120   $97,120 
Less: accumulated depreciation   (60,490)   (46,051)
Net assets under capital lease  $36,630   $51,069 

 

During the year ended December 25, 2011 the Company paid a total of $10,752 in principal payments towards capital leases. The following is a schedule of future payments required under the lease(s) together with their present values:

 

   Payments 
2012  $15,217 
2013   15,217 
2014   10,144 
2015   4,227 
Total lease payments   44,805 
Less: amount representing interest   (6,277)
Present value of minimum lease payments  $38,528 

 

Note 6 – Stockholders’ equity:

 

Stock Based Compensation

 

In September 2005, the Company adopted a stock option plan under which the board of directors may grant incentive or non-qualified stock options and stock grants to key employees, directors, advisors and consultants of the Company.

 

The maximum number of shares of stock or underlying options allowable for issuance under the plan is 700,000 shares of common stock, including 10,000 restricted shares as of December 25, 2011. Stock options vest based upon the terms within the individual option grants, usually over a five-year period at 20% per year, with an acceleration of the unvested portion of such options upon a liquidity event, as defined in the Company’s stock option agreement. The options are not transferable except by will or domestic relations order. The number of securities remaining available for future issuance under the plan was 517,000 at December 25, 2011.

 

The option price per share under the plan is not less than the fair market value of the shares on the date of the grant. The determination of the fair value of share-based payment awards is affected by the Company’s stock price. There were no stock options awards granted in 2011 or 2010.

 

F-14
 

 

GLENROSE INSTRUMENTS INC.

 

Stock option activity for the years ended December 25, 2011 and December 26, 2010 was as follows:

 

       Exercise   Weighted   Weighted     
       Price   Average   Average   Aggregate 
   Number of   Per   Exercise   Remaining   Intrinsic 
   Options   Share   Price   Life   Value 
                     
Outstanding, December 27, 2009   186,000   $7.00   $7.00    4.88   $- 
Granted   -    -    -           
Exercised   -    -    -           
Canceled   (14,000)   7.00    7.00           
Expired   -    -    -           
Outstanding, December 26, 2010   172,000   $7.00   $7.00    3.88   $- 
Exercisable, December 26, 2010   68,800        $7.00        $- 
Vested and expected to vest, December 26, 2010   172,000        $7.00    3.88   $- 
                          
Outstanding, December 26, 2010   172,000   $7.00   $7.00    3.88   $- 
Granted   -    -    -           
Exercised   -    -    -           
Canceled   (4,000)   7.00    7.00           
Expired   -    -    -           
Outstanding, December 25, 2011   168,000   $7.00   $7.00    2.88   $- 
Exercisable, December 25, 2011   134,400        $7.00        $- 
Vested and expected to vest, December 25, 2011   168,000        $7.00    2.88   $- 

 

The aggregate intrinsic value of options outstanding as of December 25, 2011 is calculated as the difference between the exercise price of the underlying options and the price of the Company’s common stock for options that were in-the-money as of that date.

 

In 2007, the Company made restricted stock grants to three of its directors by permitting them to purchase an aggregate of 15,000 shares of common stock at a price of $0.01 per share. Those shares begin to vest 90 days after the Company’s initial listing on a securities exchange or an over-the-counter bulletin board at a rate of 25% per year. All of the shares become vested shares upon a change in control prior to a termination event. There were no restricted stock awards granted in 2011 or 2010. At December 25, 2011, there were 10,000 unvested shares of restricted stock outstanding.

 

Restricted stock activity for the years ended December 25, 2011 and December 26, 2010 was as follows:

 

   Number of   Grant Date 
   Restricted Stock   Fair Value 
         
Unvested, December 27, 2009   15,000   $7.00 
Granted   -    - 
Vested   -    - 
Forfeited   -    - 
Unvested, December 26, 2010   15,000   $7.00 
           
Granted   -    - 
Vested   -    - 
Forfeited   (5,000)   7.00 
Unvested, December 25, 2011   10,000   $7.00 

 

During the years ended December 25, 2011 and December 26, 2010, the Company recognized employee non-cash compensation expense of $36,991 and $73,485, respectively, related to the issuance of restricted stock and stock options. At December 25, 2011, the total compensation cost related to unvested restricted stock awards and stock option awards not yet recognized is $19,142. This amount is expected to be recognized over a weighted average period of 1.34 years.

 

F-15
 

 

GLENROSE INSTRUMENTS INC.

 

Note 7 - Benefit plans:

 

The Company currently maintains two defined contribution 401(k) plans. Additionally, employees of ESHI are covered by a multi-employer, defined benefit plan that is not administered by the Company.

 

Eberline Services’ employees are eligible to participate in the 401(k) plan immediately. Participants may elect to contribute up to 100% of their compensation to the 401(k) Plans, subject to Internal Revenue Service annual limitations. Eberline Services makes discretionary matching contributions of up to 4.5% of a participant’s compensation, depending on deferral amount. During 2008, the Company merged the Lionville 401(k) plan into the Eberline Services plan. Contributions for Lionville employees are included in the Eberline Services contribution disclosure. For the years ended December 25, 2011 and December 26, 2010, Eberline Services contributed approximately $222,903 and $285,199, respectively.

 

Certain employees of ESHI are eligible to participate in a multi-employer, defined benefit plan (Hanford Multi-Employer Pension Plan EIN# 90-0501441) or the Plan. The Plan is administered by Mission Support Alliance, LLC on behalf of eligible, participating companies via the Hanford Pension and Savings Plans Committee. The Plan is funded by participating companies on a payroll-by-payroll basis and/or in a lump-sum annual contribution as actuarially computed by the Plan administrator. The Company expenses the computed expense amounts annually. Under the terms and conditions of the Plan, individual companies assume no liability for future pension or benefit costs associated with the Plan. The government reimburses the Company for all pension related costs as a direct project cost. For the years ended December 25, 2011 and December 26, 2010, the total expense was $942,369 and $787,795, respectively. The amounts represented less than five percent of the total Plan contributions during each year respectively. As of December 25, 2011, the Plan was not subject to a funding improvement Plan. As of December 25, 2011, the Plan was funded at an amount greater than 80% of future benefits. For the years ending December 25, 2011 and December 26, 2010, 157 and 160 employees participated in the Plan respectively. Additional information is publically available in the Plan’s annual Form 5500 filing.

 

Additionally, ESHI employees are eligible to participate in a traditional, employer-sponsored 401(k) plan also administered by Fluor Hanford, Inc. For the years ended December 25, 2011, and December 26, 2010, employer contributions were $815,030 and $653,168, respectively.

 

Note 8 – Related party transactions:

 

On July 25, 2008, the Company entered into subscription agreements with four investors for the sale of convertible debentures in the aggregate principal amount of $14,875,000. The primary investor was Blum Strategic Partners IV, L.P., who subscribed for $12,000,000 of the debentures. Additional investors included John N. Hatsopoulos, the Company’s Chairman of the board, Arvin H. Smith, the Company’s President and Chief Executive Officer, and Philip Frost M.D., a holder of more than 10% of the outstanding equity securities of the Company immediately prior to the sale of the debentures, who subscribed for $2,875,000 of debentures by exchanging existing promissory notes of the Company for the debentures. The debentures carried interest at 4%, payable quarterly in cash, and matured on July 25, 2013. The debentures were convertible at the option of the holder at any time into shares of common stock at a conversion price equal to $7.00 per share.

 

On July 23, 2010, the holders of the outstanding principal amount of the Company’s convertible debentures, agreed to amend the debenture agreements to eliminate subsections (i) and (ii) of Section 6(a) of the debentures. With this amendment the holders gave the Company the option to redeem any portion of the debentures by written notice to the holders; provided that a redemption notice is delivered by the Company and be received by the holder of the debentures at least ten (10) trading days but not more than thirty (30) trading days prior to the date of the redemption. In connection with the amendment described above, the Company redeemed $10,000,000 on August 9, 2010, $575,000 on January 13, 2011, and $500,000 on March 31, 2011.

 

On July 1, 2011, the Company redeemed the outstanding amount of the convertible debentures with Blum Strategic Partners IV, L.P., in the principal amount of $3,065,546, plus accrued interest. In connection with that transaction, the Company entered into a $500,000 Demand Note Agreement with John N. Hatsopoulos, the Company’s Chairman of the Board, and into a $1,500,000 Demand Note Agreement with Arvin H. Smith, the Company’s Chief Executive Officer. Both demand note agreements accrued interest at the rate of 4.50% per year.

 

The Company’s Chief Financial Officer devotes part of his business time to the affairs of American DG Energy Inc., or American DG, that pays his salary and part of his salary is reimbursed by the Company. The Chief Executive Officer of American DG is the Chairman of the Board and a significant investor in the Company.

 

F-16
 

 

GLENROSE INSTRUMENTS INC.

 

Note 9 – Earnings per share:

 

The Company’s earnings per share basic and diluted for the years ended December 25, 2011 and December 26, 2010 were as follows:

 

   2011   2010 
Earnings per share          
Earnings available to stockholders  $1,285,922   $1,149,399 
           
Weighted average shares outstanding - basic   3,102,647    3,102,647 
Net earnings per share - basic  $0.41   $0.37 
           
Assumed exercise of dilutive stock options and warrants   -    - 
Weighted average shares outstanding - diluted   3,102,647    3,102,647 
Net earnings per share - diluted  $0.41   $0.37 
           
Anti-dilutive restricted stock outstanding   10,000    15,000 
Anti-dilutive shares underlying stock options outstanding   168,000    173,000 
Anti-dilutive convertible debentures   -    696,429 

 

Note 10 – Fair value measurements:

 

The fair value topic of FASB’s Accounting Standards Codification defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The accounting guidance also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. There are three levels of inputs that may be used to measure fair value:

 

Level 1 — Unadjusted quoted prices in active markets for identical assets or liabilities. At December 25, 2011, the Company had cash of $12,305 in Level 1 financial assets or liabilities.

 

Level 2 — Observable inputs other than quoted prices included in Level 1. Level 2 inputs include quoted prices for identical assets or liabilities in non-active markets, quoted prices for similar assets or liabilities in active markets and inputs other than quoted prices that are observable for substantially the full term of the asset or liability. At December 25, 2011, the Company had $451,406 in restricted assets that are comprised of certificates of deposits in Level 2 financial assets or liabilities.

 

Level 3 — Unobservable inputs reflecting management’s own assumptions about the input used in pricing the asset or liability. The Company currently does not have any Level 3 financial assets or liabilities.

 

The following table presents information about the Company’s financial assets measured at fair value on a recurring basis as of December 25, 2011:

 

       Quoted   Significant     
       Prices   Other   Significant 
       in Active   Observable   Unobservable 
   December 25,   Markets   Inputs   Inputs 
   2011   (Level 1)   (Level 2)   (Level 3) 
                 
Assets                    
Money market funds (1)  $12,305   $12,305   $-   $- 
Certificates of deposit (2)   451,406    -    451,406    - 
Total Assets  $463,711   $12,305   $451,406   $- 

__________________

 

(1)Money market funds are included within short term investments.
(2)Certificates of deposits are included within restricted assets. The Company determines the fair value of certificates of deposits using information provided by the issuing bank which includes discounted expected cash flow estimates using current market rates offered for deposits with similar remaining maturities.

 

F-17
 

 

GLENROSE INSTRUMENTS INC.

 

The following table presents information about the Company’s financial assets measured at fair value on a recurring basis as of December 26, 2010:

 

       Quoted   Significant     
       Prices   Other   Significant 
       in Active   Observable   Unobservable 
   December 26,   Markets   Inputs   Inputs 
   2010   (Level 1)   (Level 2)   (Level 3) 
                 
Assets                    
Money market funds (1)  $12,305   $12,305   $-   $- 
Certificates of deposit (2)   450,000    -    450,000    - 
Total Assets  $462,305   $12,305   $450,000   $- 

__________________

 

(1)Money market funds are included within short term investments.
(2)Certificates of deposits are included within restricted assets. The Company determines the fair value of certificates of deposits using information provided by the issuing bank which includes discounted expected cash flow estimates using current market rates offered for deposits with similar remaining maturities.

 

Note 11 - Income taxes:

 

Components of the provision for income taxes for the years ended December 25, 2011 and December 26, 2010 were as follows:

 

Provision (benefit) for income taxes  2011   2010 
Current taxes:          
Federal  $662,955   $18,130 
State   -    - 
Total current taxes   662,955    18,130 
           
Deferred taxes:          
Federal   73,099    (47,037)
State   -    - 
Total deferred taxes   73,099    (47,037)
Total income tax provision (benefit)  $736,054   $(28,907)

 

The income tax expense for the years ended December 25, 2011 and December 26, 2010 varied from the amount computed by applying the federal statutory income tax rate to income before taxes. Reconciliation between the federal statutory taxes and effective taxes follows:

 

Reconciliation between federal statutory taxes and effective taxes  2011   2010 
         
Federal taxes at the statutory rate applied to income before taxes  $687,472   $380,967 
Add (deduct):          
State income tax expense net of federal benefit   64,408    36,102 
Stock-based compensation   12,577    24,985 
Adjustment to valuation allowance   -    (453,574)
Other accruals and adjustments   (28,403)   (17,387)
Total income tax expense (benefit)  $736,054   $(28,907)

 

F-18
 

 

GLENROSE INSTRUMENTS INC.

 

Deferred income taxes reflect the net tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred taxes at December 25, 2011 and December 26, 2010, were as follows:

 

Deferred taxes  2011   2010 
         
Deferred tax liabilities:          
Depreciable assets  $(598,660)  $(518,262)
           
Deferred tax assets:          
Intangible assets   65,350    81,354 
Accrued liabilities   507,248    479,584 
NOL carryforwards   477,532    482,727 
Valuation allowance   (477,532)   (478,366)
    572,598    565,299 
Net deferred taxes  $(26,062)  $47,037 

 

The Company recorded a tax provision of $736,054 in 2011 compared to a tax benefit of $28,907 in 2010. As of December 25, 2011, the Company had a deferred tax asset balance of $572,598 a portion of which is related to $1,284,794 of net operating losses at Lionville. These Lionville losses are subject to separate return limitation year treatment and may only be utilized against income from Lionville. As of December 25, 2011, the Company believed that it was more likely than not that it would not realize the balance of these Lionville assets, and therefore reduced the deferred tax asset by a valuation allowance in the amount of $477,532. The Lionville net operating losses expire by December 2029 and 2030, respectively.

 

As of December 25, 2011, the Company had no accrued liability for unrecognized tax benefits related to various federal and state income tax matters. The Company does not expect that the amounts of unrecognized tax benefits will change significantly within the next 12 months. The Company recognizes interest and penalties relating to income tax matters in operating expenses. The Company’s tax years from 2006 to 2011 remain subject to examination by major tax jurisdictions.

 

Note 12 - Segment data:

 

The Company’s executive officers include Arvin Smith, Dr. Richard Chapman and Dr. Shelton Clark. Collectively, they are the Chief Operating Decision Maker, or CODM, as defined by Disclosures about Segments of an Enterprise and Related Information. The office of the CODM is responsible for assessing the performance of each segment, as well as the allocation of Company resources.

 

The Company currently operates three business segments: Environmental Services, Analytical Laboratories and Instruments. The Environmental Services operating segment provides radiological and waste management services primarily to the federal government in connection with the clean-up of the former and present atomic weapons and energy sites operated by the federal government. The Analytical Laboratories operating segment provides analytical radiological services and involves the operation of a radiochemistry laboratory network and a radioactive check source manufacturing facility. The Instruments segment was formed in 2006 with the intent to acquire instrument companies, which have well-established and proven technology. This segment also includes the research and development of a new line of instruments that the Company expects to begin marketing efforts in 2012. As of the date of this report the Company has not made any commitments, nor has it acquired any instrument businesses. Acquisition of instrument businesses is no longer a focus in the Company’s strategy. Intercompany costs and sales are eliminated in the consolidated financial statements.

 

F-19
 

 

GLENROSE INSTRUMENTS INC.

 

Segment data for the years ended December 25, 2011 and December 26, 2010 are included below: 

 

   2011   2010 
         
Revenues          
Environmental Services  $34,464,753   $30,799,943 
Analytical Laboratories   10,022,764    10,145,319 
Instruments   -    - 
    44,487,517    40,945,262 
Cost of Sales          
Environmental Services   31,213,256    28,255,733 
Analytical Laboratories   8,738,954    8,479,524 
Instruments   -    - 
    39,952,210    36,735,257 
Gross Profit          
Environmental Services   3,251,497    2,544,210 
Analytical Laboratories   1,283,810    1,665,795 
Instruments   -    - 
    4,535,307    4,210,005 
General and administrative expenses          
Environmental Services   1,500,838    1,507,384 
Analytical Laboratories   401,823    420,200 
Instruments   339,429    388,809 
    2,242,090    2,316,393 
Operating profit (Loss)          
Environmental Services   1,750,659    1,036,826 
Analytical Laboratories   881,987    1,245,595 
Instruments   (339,429)   (388,809)
    2,293,217    1,893,612 
Supplemental Disclosure          
Depreciation Expense          
Environmental Services   113,924    66,323 
Analytical Laboratories   404,833    365,422 
Instruments   -    - 
    518,757    431,745 
Capital Expenditures          
Environmental Services   190,111    143,472 
Analytical Laboratories   298,764    194,897 
Instruments   -    - 
   $488,875   $338,369 
           
Total Assets          
Environmental Services   9,414,532    8,905,345 
Analytical Laboratories   3,132,814    4,250,758 
Instruments   146,876    119,452 
   $12,694,222   $13,275,555 

 

Note 13 – Subsequent events:

 

The Company has evaluated subsequent events through the date of this filing and determined that no other subsequent events occurred that would require recognition in the consolidated financial statements or disclosure in the notes thereto.

 

F-20